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Hormonal contraceptives and the acquisition of sexually transmitted infections: an updated 
systematic review 
Sexually Transmitted Diseases 
 
Dear Dr. Miller, 
 
Thank you for the careful review of our systematic review on the relationship between hormonal 
contraception and incident sexually transmitted infections.  We have responded to each of the 
reviewers’ comments as indicated in the attached document.  We appreciate the reviewer’s 
comments which have strengthened the manuscript. 
 
Attached please find a revised version of the manuscript for your consideration. 
 
With kind regards, 
 
 
Heidi E. Jones, PhD MPH 
Associate Professor, Dept. of Epidemiology & Biostatistics 
CUNY School of Public Health 
 
 
 
 
 
  
Revision letter/Changes & rebuttals
Reviewer #1: 
The authors conducted a systematic review of recent studies of contraceptive use and 
acquisition of sexually transmitted infections. Overall, the product is good and the conclusions 
are balanced and forward-looking. Several comments: 
 
1. Timing. My strongest question is why limit the data to 2009-2017 rather than update 
from all prior data. The authors note that reviews of HIV as an outcome have been 
routinely updated - and of course those built on prior data, not just took time-period 
chunks. The limiting of the time period, rather than updating, is central to the approach 
and needs a strong justification. 
 
Thank you to the reviewer for this comment.  As two previous systematic reviews had been 
implemented (Mohllajee et al., 2006; Morrison et al. 2009), we restricted our search to 2009-
2017.  The previous reviews found notable methodological limitations in the majority of articles 
identified, many of which were cross-sectional studies.  In hindsight, however, we should have 
included prospective studies that met our criteria in our review.  We have now reviewed the 
articles identified in the two previous studies, of which 8 met our criteria.  These articles have 
been added to the tables, figures and text, as appropriate, based on our quality assessment. 
 
2. Abstract and later. The use of "strong evidence" and "weak evidence" as terms is a bit 
guidelines-like, and standard definitions for such guidelines work do not seem to have 
been applied here (and probably would not be appropriate). Perhaps other descriptions 
could be used. 
 
We have qualified the ‘strong’ and ‘weak’ evidence description of study results for DMPA on 
trichomoniasis and HSV-2. Instead we comment on the number of studies/consistency of 
findings and magnitude of effect size. This was done in the abstract and discussion/conclusions. 
 
3. Abstract. The species name for Neisseria gonorrhoeae is misspelled. 
 
This has been corrected. 
 
4. Introduction. The statement that DMPA results in immune suppression is arguably an 
overreach; there may be immune modulation but "immune suppression" has a 
commonly-used sense (e.g., resulting in targeted or broad susceptibility to a host of 
infections, like in advanced AIDS, cancer therapy, etc.) which is obviously not 
appropriate. 
 
We have revised the sentence accordingly (page 4). 
 
5. Conclusions. Obviously, the question of contraceptive use and HIV risk has been 
much more in the spotlight than STIs. The HIV data has accumulated through secondary 
analysis of large HIV endpoint (observational or clinical trials of prevention interventions) 
studies and the ongoing ECHO randomized trial. It would not be too much, arguably, to 
advocate in this article for large studies of women such as these to include / analyze STI 
outcomes so the evidence base can grow. 
 
We agree that more research is needed and have added a sentence highlighting the addition of 
STI outcomes to HIV research in lines 470-471 as follows: 
 
 
“Existing large-scale prospective studies of HIV risk among women should incorporate well 
measured contraceptive use and STI outcomes to help address these gaps.” 
 
Reviewer #2: 
Overall, this is a comprehensive and nicely organized and written systematic review on 
an important subject - the effect of hormonal contraception on STIs. There have been no 
published systematic reviews on this subject since 2008 (although another is in press) 
and thus it is important to update our understanding of these relationships - especially 
given the epidemiologic and biologic evidence suggesting a possible relationship 
between DMPA and HIV acquisition. 
 
Specific Comments 
Methods 
1. The fact that the protocol was registered with PROSPERO and followed the PRISMA 
guidelines is appropriate for this systematic review and suggests rigorous methodology. 
 
Thank you. 
 
2. Important that the authors limited to prospective studies with outcomes defined by 
laboratory diagnostic tests. 
 
Thank you. 
 
3. Line 95-96. You say that a third reviewer resolved discrepancies. It appears that the 
third reviewer (HEJ/ELG) is one of the two original reviewers. Please clarify this. 
 
To clarify, all studies were double reviewed. One reviewer extracted results from all studies 
[KM], while ELG and HEJ each independently reviewed half. Discrepancies were resolved by a 
third reviewer who had not originally reviewed the study (HEJ resolved discrepancies between 
KM and ELG; ELG resolved between KM and HEJ). This has been clarified in the text on page 6 
as follows: 
 
“Two independent reviewers [KJM & HEJ or ELG] screened each abstract or article using 
Covidence software; a third reviewer who had not previously reviewed the study [HEJ or ELG] 
resolved discrepancies.” 
 
4. Line 110-111. What happens if the two reviewers did not agree on their rating of study 
quality. How was this resolved? 
 
Discrepancies were resolved through discussion between the reviewers.  We have clarified this 
in the text in lines 130-131 as follows: 
 
“Two reviewers [KJM & HEJ or ELG] independently rated study quality; discrepancies were 
resolved by discussion among all three reviewers.” 
 
5. The authors seemed to have used a comprehensive search strategy for hormonal 
contraception and STIs. 
 
Thank you. 
 
Results 
 
1. Line 122. I think the authors should make it clearer that the analysis from the RCTs and 
nested case control are also observational analyses. They could make a blanket 
statement here that all analyses were observational and then break down the types of 
studies the data originated from. 
 
Thank you for this suggestion, we have made the suggested revision on page 7 as follows: 
 
“The 30 reviewed studies were all prospective and observational in design, most were 
longitudinal cohort studies (N=25), four were secondary analysis of a randomized control trial 
[23,24,34,35] and one used a nested case-control design [36].” 
 
2. Line 136. It would be good to state what the non-hormonal methods are. 
 
Non-hormonal methods were, for the large part, not specified in the reviewed studies. However, 
we revised to include example methods (e.g., condoms) in lines 181-184 as follows: 
 
“Half of the studies (15 of 30) compared HC users to non-hormonal method users (e.g., 
condom), twelve studies compared two or more types of HCs [23,24,52,54,26–
28,36,39,40,43,44], three compared HC use to women not using any method and/or women 
who were sterilized [21,22,46].”  
  
3. Line 146. Not sure if it really makes sense to include articles that cannot distinguish 
between COC and POPs. There are important reasons to believe that these different pills 
could have different effects on STI acquisition. I would consider dropping these studies. 
 
We agree that it is a large limitation when the type of OCP (COC or POP) is not specified as the 
biological mechanism involved is greatly different and has implications for STI susceptibility. We 
found that only 5 of the 24 studies which assessed STI risk following OCP use specified the 
type of OCP. Dropping studies without specification would therefore result in too few for 
analysis. We highlight this limitation in our Abstract conclusion as follows: 
 
“Future studies should specify the type of injectable or OCP used to increase understanding of 
biological pathways..” 
 
We also highlight this in our results section on page 8 as follows: 
 
“Most studies (19 of 24) did not distinguish between combined or progestin only OCPs, and 
some did not distinguish between DMPA and Net-En injectable (3 of 19).” 
 
Further we have updated our discussion on page 18 as follows: 
 
“Further many of the studies of OCPs did not differentiate between combined or progestin-only 
OCPs and similarly some injectable studies did not differentiate between Net-En and DMPA.  
Given that biological responses to HC differ by class of drug as well as drug formulations, [5] 
future research needs to distinguish between HC formulations when estimating risk of STI/HIV 
acquisition.”   
 
4. Line 177. Not only are the reference groups inconsistent but they could include users 
of other contraceptive methods in the reference group. This makes it even harder to 
interpret. 
 
We agree and have added this as an additional complication on page 8 as follows: 
 
“The reference group of non-users of a given HC was not defined consistently and sometimes 
included users of other forms of contraception.”   
 
5. Line 199. I would not say that the effect was 'attenuated'. Really there is little 
meaningful difference between the two effect estimates or confidence intervals. 
 
We have revised our description of the results as follows: 
 
“The other study found DMPA use relative to non-DMPA use was strongly associated with HSV-
2 acquisition among women both living with and without HIV (aHR: 4.43, 95%CI: 1.90, 10.35), 
and when restricted to women living without HIV (aHR: 3.97, 95%CI: 1.64, 9.60) [54].” 
 
6. Line 227: I would say a 'non-significant' reduced risk as you are specifying this in other 
places in the manuscript. 
 
We have made the suggested change. 
 
7. Line 235: I would say "injectable type unspecified' to be clear. 
 
Thank you, we have made the suggested change. 
 
8. Line 264: "Two studies … evidence of reduced risk". You already said this in line 261. 
Are these the same studies? Please clarify. 
 
We have clarified that we intended to say ‘Of the two studies which documented significant 
evidence of reduced risk…’ and then to further describe results from the two studies. This has 
been corrected in the text, only now three studies are discussed (see revisions lines 385-391. 
 
9. Line 293. 'weaker evidence of increased risk of HSV-2 incidence'. There may only be 3 
studies for DMPA and HSV-2 as opposed to six studies for DMPA and Tv. However, the 
raised effect estimated for DMPA and HSV-2 are much stronger than the reduced effect 
estimates for DMPA and TV. I would mention that and consider that in your conclusions 
about the relative strength of evidence for these relationships. 
 
The Reviewer raises an important point. and we clarify that by ‘weak evidence’, we were 
referring to the small number of studies that assessed the association and not the effect size or 
biological plausibility. We agree that the magnitude of effect is also an important consideration. 
We have qualified our description of the ‘strength’ of study findings by both these criteria, as 
suggested, in the abstract in lines 45-47 as follows: 
 
“Depo-medroxyprogesterone acetate (DMPA) reduces the risk of trichomoniasis (consistent 
evidence) and may increase the risk of HSV-2 (strong effect, few studies.” 
 
We have also updated the discussion in lines 430-432 as follows: 
 
“Among studies of sufficient quality, DMPA use is consistently associated with a reduced risk of 
T. vaginalis acquisition, with evidence of substantial (two times or higher) increased risk of HSV-
2 incidence from a smaller number of studies.” 
 
10. Line 295 OC and Tv. I find the evidence for DMPA and increased HSV-2 to be stronger 
than the evidence for OC and reduced TV incidence. Please address the reasons why you 
say the evidence for HSV-2 is limited but do not say this for OCs and Tv. 
 
See our response to comment 9 above. 
 
11. Evidence Tables: Nice job here. I would add the reference number to the first column 
with the first author and date. This makes it easier for the reader to look something up. 
 
We have added the reference number of cited studies to the data tables, as suggested. 
 
12. Under the OCP column of the evidence table, I would make it clear whether you are 
referring to COC, POP, or type unspecified. 
 
Results reported under the OCP column of the evidence tables specifies whether the type of pill 
was COC (if combined pill was specified by study authors), POP (progestin-only) or as OCP if 
otherwise unspecified (as generally few studies specified the type of pill). This was previously 
described in the table notes, which we have changed to footnote ‘a’. This notation was adopted 
as few studies specified the type of OCP. 
 
13. Figures: Nice job on the Forest Plots. However, is there some important reason why 
the estimated risk is on the log scale? Most readers are much more familiar with seeing 
effect estimates expressed as OR/ RR/HR with the null being 1.0 rather 0.0. Also, I take it 
you didn't include Forest Plots for other relationships because there are too few studies. 
Is that correct? 
 
We plotted the estimated risk on the log scale for two reasons:  1. This approach ensures that 
the 95% confidence intervals are symmetrical around the point estimate; and 2. This approach 
ensures that preventive and causal effects are presented visually on the same scale, which is 
not the case when plotted on the OR/HR/RR scale.  For example, a RR of 2 is not visually 
equivalent to a RR of 0.5 on the OR/HR/RR scale. However, these estimates are equivalent on 
the log scale.  The reviewer is correct that we did not include forest plots for other examined 
associations because the number of studies was small (<5) and forest plots are most useful 
when interpreting results across several studies. 
 
14. Nice supplemental tables. Why don't you put all the references together in the body of 
the paper? Is that a Sexually Transmitted Diseases rule that you can only have 30 
references in the body of the paper? 
 
The reviewer is correct, the journal does not permit more than 30 references in the body of the 
paper and we have included them in the Appendix to keep with the guidelines. 
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Abstract  31 
Background: Evidence suggests that some forms of hormonal contraception (HC) increase 32 
women’s risk of non-HIV sexually transmitted infections (STIs), yet evidence has not been 33 
reviewed since 2008. We conducted an updated systematic review to incorporate studies 34 
published between January 2009 and June 2017 to examine the relationship between HCs and 35 
incident and/or recurrent STIs. 36 
Methods: We searched PubMed and EMBASE to identify prospective studies comparing risk of 37 
Chlamydia trachomatis, Neisseria gonorrhoeae, human papillomavirus (HPV), herpes simplex 38 
virus type 2 (HSV-2), Treponema pallidum, or Trichomonas vaginalis, between women using HC 39 
vs. non-hormonal methods or no methods. We summarize results by type of STI and HC and 40 
study quality using an adapted Newcastle-Ottawa Quality Assessment Scale. 41 
Results: Thirty articles met the inclusion criteria. Depo-medroxyprogesterone acetate (DMPA) 42 
reduces the risk of trichomoniasis (consistent evidence) and may increase the risk of HSV-2 43 
(strong effect, few studies); inconclusive evidence exists for HPV, chlamydia, gonorrhea and 44 
syphilis. Data on oral contraceptive pills (OCPs; generally not differentiated whether combined 45 
or progestin-only pills) suggest use is associated with a reduced risk of trichomoniasis with 46 
inconclusive findings for HSV-2, HPV, chlamydia, gonorrhea, and syphilis. Very few studies 47 
included norethisterone enanthate (Net-En) injectable, implants or the levonorgestrel IUD. 48 
Conclusions: DMPA and OCPs reduce the risk of trichomoniasis and DMPA may increase the risk 49 
of HSV-2. However, the potential for confounding cannot be ruled out. Future studies should 50 
specify the type of injectable or OCP used to increase understanding of biological pathways; 51 
more research is needed on implants and hormonal IUDs.  52 
 4 
Introduction 53 
While access to hormonal contraception (HC) reduces unwanted pregnancy and maternal 54 
morbidity and mortality, a body of evidence from recent systematic reviews, meta-analyses and 55 
in vivo and in vitro studies suggest that the progestin injectable depo-medroxyprogesterone 56 
acetate (DMPA) increases risk of HIV acquisition [1–5]. Comparatively less emphasis, however, 57 
has focused on the potential association of DMPA and other HC and other sexually transmitted 58 
infections (STIs).  59 
 60 
Several biological mechanisms by which HC use may facilitate STI acquisition have been 61 
proposed including through changes in the protective cervicovaginal epithelial barrier 62 
from hypo-estrogenism induced by progestin-only methods [6,7]. A second mechanism is 63 
through weakening of immune defense [8]. For example, DMPA is known to bind to 64 
glucocorticoid receptors, which generally results in immune modulation [5,9]. Third, hypo-65 
estrogenism induced by progestin-only methods could lead to changes in the vaginal microbiota 66 
composition, leading to vaginal dysbiosis and inflammation [10], which in turn could lead to 67 
epithelial breaches and mucus degradation [11,12]. At a behavioral level, HC use may result in 68 
decreased condom use, thereby increasing risk of STI exposure [13,14].  69 
 70 
Two prior systematic reviews have examined the association between HCs and STI acquisition; 71 
evidence has not been synthesized since 2008 [15,16]. Both reviews found that OCP and DMPA 72 
users had a possible increased risk of chlamydia but concluded there was inconclusive evidence 73 
for gonorrhea, herpes simplex virus type 2 (HSV-2), trichomoniasis, syphilis and human 74 
 5 
papillomavirus (HPV). Given the magnitude of women using HC globally and the negative health 75 
repercussions of many STIs, we conducted an updated systematic review to incorporate 76 
literature from longitudinal studies published between 2009 and 2017 on the association 77 
between the HC use and non-HIV STI acquisition; systematic reviews on HIV acquisition have 78 
been updated regularly [1–4].   79 
 80 
Materials and Methods 81 
The protocol was registered a priori with PROSPERO [Record 42017069357] and follows PRISMA 82 
guidelines (Supplemental Table 1). Articles were identified using key term searches of two 83 
electronic databases: PubMed and EMBASE (Supplemental Figure 1).  84 
 85 
Inclusion/exclusion criteria 86 
Included articles were peer reviewed, published in English, Spanish or French between 01 87 
January 2009 and 30 June 2017 and measured incident/recurrent cases of cervicovaginal HPV, 88 
HSV-2, chlamydia, gonorrhea, syphilis, and/or trichomoniasis, with laboratory diagnostic tests, 89 
among HC users compared with non-users or users of non-hormonal methods. All HC methods 90 
were included except for emergency contraception, since it is typically used in combination 91 
with other contraceptive methods [17].  We also reviewed articles identified from two earlier 92 
systematic reviews [15,16]; articles from these reviews which met our criteria are also included. 93 
 94 
We excluded cross-sectional studies, review articles, studies which relied on clinical exam or 95 
self-reported STIs, and studies which did not control for potential confounding variables. We 96 
 6 
also excluded studies of HCs and HIV and bacterial vaginosis (BV), as both have been recently 97 
reviewed [18,19]. Two independent reviewers [KJM & HEJ or ELG] screened each abstract or 98 
article using Covidence software; a third reviewer who had not previously reviewed the study 99 
[HEJ or ELG] resolved discrepancies. 100 
 101 
Data Extraction 102 
One reviewer [KJM] extracted data, with independent review for accuracy [HEJ or ELG]. 103 
Extracted information included: participant characteristics, geographic location, sample size, 104 
sampling method, contraceptive method, duration of use, comparison group, STI, whether 105 
infection was incident or recurrent, STI diagnostic test, confounders in adjusted estimates, type 106 
of statistical analysis, treatment of missing data, length of time between exposure and outcome 107 
assessment, and the effect estimate, variance and significance level.  108 
 109 
Study quality 110 
Risk of bias was assessed using the Newcastle-Ottawa Quality Assessment Scale [20], adapted 111 
to reflect challenges identified previously for assessment of the relationship between HC use 112 
and STIs/HIV [3,15] (Supplemental Tables 2 and 3). Two reviewers [KJM & HEJ or ELG] 113 
independently rated study quality; discrepancies were resolved by discussion among all three 114 
reviewers.  115 
 116 
Data synthesis 117 
 7 
Our primary outcome is incident STI. We examined findings by HC method used (e.g., OCP, 118 
DMPA, levonorgestrel IUD, Net-En, Norplant) and type of STI. Forest plots were constructed 119 
using the forestplot package in R Studio (Version 1.1.383, Vienna, Austria).  120 
 121 
Results 122 
Our key term search resulted in 1,477 unique articles, 1,284 articles were excluded during 123 
abstract screening; 24 required full-text review of which two were excluded (Figure 1). An 124 
additional 13 prospective studies identified in the previous two systematic reviews were 125 
considered for inclusion. Of these eight met our study inclusion criteria and are included [21–126 
28], five did not meet our criteria [29–33]. The 30 reviewed studies were all prospective and 127 
observational in design, most were longitudinal cohort studies (N=25), four were secondary 128 
analysis of a randomized control trial [23,24,34,35] and one used a nested case-control design 129 
[36].  130 
 131 
The majority of articles assessed the incidence or recurrence of HPV (n=13) [26,27,43–132 
45,28,36–42], followed by trichomoniasis (n=9) [21,24,34,37,46–50], chlamydia (n=9) [21–133 
23,37,47,48,50–52], gonorrhea (n=7) [21–23,37,47,48,50], HSV-2 (n=4) [35,37,53,54], and 134 
syphilis (n=3) [24,37,47] (not mutually exclusive). Two studies combined incident chlamydia 135 
and/or gonorrhea [25,55]. Twelve studies included women ages 18-50 years [22–136 
24,27,36,37,41,42,48,51,53,55], ten studies included adolescents (<age 18 years) 137 
[21,25,26,28,35,44,46,47,50,52], three included women older than age 49 years [34,45,47] and 138 
five did not report age range, but the majority of participants were of reproductive age [38–139 
 8 
40,43,49]. One-third of studies enrolled populations considered at increased STI risk: women 140 
reporting transactional sex (n=6) [21,22,37,51,53,54], injection drug use (n=1) [43], lower 141 
genital tract infection/partner with diagnosed STI (n=1) [52], or living with HIV (n=2) [22,55]. 142 
Three additional studies included women living with and without HIV [43,46,54]. 143 
 144 
Half of the studies (15 of 30) compared HC users to non-hormonal method users (e.g., condom), 145 
twelve studies compared two or more types of HCs [23,24,26–28,36,39,40,43,44,52,54], three 146 
compared HC use to women not using any method and/or women who were sterilized 147 
[21,22,46].  148 
 149 
Study quality assessment and risk of bias 150 
Most studies were considered high (n=8) or medium (n=19) quality (Supplemental Tables 2 and 151 
3). Low quality studies (n=3) are presented in the data tables, but not included in forest plots or 152 
discussed [40,45,47].  153 
 154 
Despite medium/high quality, a number of methodological challenges remained. Nearly all 155 
studies relied on self-reported HC exposure, despite known limitations [9]. Most studies (20 of 156 
25) did not distinguish between combined or progestin only OCPs, and some did not distinguish 157 
between DMPA and Net-En injectable (3 of 19). The reference group of non-users of a given HC 158 
was not defined consistently and sometimes included users of other forms of contraception.  159 
Most studies employed empirically driven rather than theoretical adjustment for confounding. 160 
 9 
Non-significant estimates were not always presented, prohibiting information on the direction 161 
of association. For some studies, incidence rates were low suggesting limited power.  162 
 163 
HPV 164 
Eleven studies evaluated the risk of HC on incident HPV infection and provide inconclusive 165 
evidence of association (Table 1, Figure 2). All diagnostic tests were DNA-based and five 166 
assessed one or more high-risk HPV (HR-HPV) types, one assessed one or more low-risk HPV 167 
(LR-HPV), while eight considered any HPV type; two disaggregated results more than one way. 168 
Four studies assessed the influence of injectables; two found that incidence of HR (one study) 169 
or any HPV (one study) was lower but not significantly lower compared to non-HC users [37,41]. 170 
A third study found recent DMPA users had increased incident HR-HPV (used in past six months 171 
aOR: 1.6; 95%CI: 0.7, 3.7) and long-term users (≥1 year of use aOR: 4.7; 95%CI: 1.4, 15.8) 172 
relative to non-users of DMPA [36]. Findings were in the same direction but not statistically 173 
significant among short term and former users. The fourth study found non-significant results in 174 
mixed directions, depending on HPV type [44]: DMPA use was associated with lower incidence 175 
of HR and increased risk of LR-HPV. 176 
 177 
Ten studies evaluated OCP use. Three reported OCP use to be associated with increased HPV 178 
risk [27,42,44], two found non-significant increased risk, [37,41] one found significant 179 
decreased risk [26], two reported non-significant decreased risk [28,36], one found no effect 180 
[38] and one did not report the effect estimate for non-significant findings [43]. Only two 181 
studies specified combined OCP use (COC), both documented a non-significant association 182 
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[36,41]. Of the studies which documented evidence of increased risk, one was among OCP users 183 
vs. non-OCP users in the last three months among LR-HPV (aHR: 2.73; 95%CI: 1.52, 4.90) and 184 
all-HPV types (aHR: 2.0; 95%CI: 1.28, 3.15), but not HR-HPV types [44]. Another study which 185 
also assessed OCP users vs. non-OCP users on all-HPV types found a lower magnitude of 186 
increased risk (aHR: 1.40, 95%CI: 1.01, 1.80) [27]. The final significant finding of increased risk 187 
was documented in the longest exposure group only (7+ years) (aOR: 1.66; 95%CI: 1.17, 2.35), 188 
with attenuated evidence of marginal risk in lower exposure groups (5-6 year and 3-4 year 189 
groups) and null effects among users <2 years relative to nonusers of HC [42]. The one study 190 
that found significant decreased risk was among OCP using U.S. women attending a family 191 
planning clinic relative to non-current OCP users (aHR: 0.49, 0.28, 0.86) [26]. Overall, 192 
inconsistent exposure groups (current versus ever user), reference group (non-current versus 193 
never user) and differences in HPV-subtype may contribute to disparate findings. 194 
 195 
Only one study assessed the risk of hormonal IUD use on incident HPV infection. This 196 
retrospective record review compared levonorgestrel IUD users to copper IUD users and 197 
documented a four-fold higher risk of HR-HPV among the former [39]. This effect was 198 
marginally significant and based on few incident cases. 199 
 200 
HSV-2  201 
Studies examining HSV-2 acquisition provide some evidence that injectable use increases risk 202 
[35,37,54] and inconclusive evidence regarding OCPs [35,37,53,54] (Table 2).  203 
 204 
 11 
Three studies examined the risk of injectable use on HSV-2 incidence. Two studies reported 205 
evidence of a significantly increased risk following injectable use (one specifies DMPA, the other 206 
is unspecified) [35,54]. The remaining study reports evidence of non-significant increased risk 207 
(injectable type unspecified) [37]. The two studies that did not record the injectable type 208 
reported that DMPA was most common. Of the two studies that documented a significant 209 
effect, one study among HIV-negative women in Uganda reported increased risk (aOR: 2.26, 210 
95%CI: 1.09, 4.69) among consistent DMPA users, but not those who discontinued use, relative 211 
to non-HC users [35]. The other study found DMPA use relative to non-DMPA use was strongly 212 
associated with HSV-2 acquisition among women both living with and without HIV (aHR: 4.43, 213 
95%CI: 1.90, 10.35), and when restricted to women living without HIV (aHR: 3.97, 95%CI: 1.64, 214 
9.60) [54]. The third study documented non-significant evidence of increased risk among HIV-215 
negative women who engaged in sex work and used DMPA (aOR: 6.34, 95%CI: 0.25, 158.5) 216 
compared to non-HC users, [37] based on only five incident cases among DMPA users. 217 
 218 
Three studies examined HSV-2 acquisition among OCP users: two documented a non-significant 219 
reduced risk of HSV-2 among OCP users relative to non-HC users [35,53]. The remaining study 220 
was in the harmful direction but was based on only two incident cases among OCP users [37].  221 
 222 
Chlamydia  223 
Seven studies provide inconclusive evidence of increased risk of chlamydia among injectable 224 
users [21,22,37,48,50–52] and three provide inconclusive evidence regarding OCP use 225 
[23,37,51] (Table 3, Figure 3).  226 
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 227 
Of the seven studies among injectable users, three documented a significant increased risk of 228 
acquisition among DMPA users [21,22,51]. The magnitude of increased risk ranged between 1.6 229 
(95%CI: 1.1, 2.4) fold among DMPA users relative to women who were sterilized or using no 230 
contraception [21] to 3.1 (95%CI: 1.0, 9.4) among women living with HIV-1 who used DMPA 231 
compared to those who were sterilized or used IUD [22]. The latter effect was marginally 232 
significant (p=0.05). Four studies found a non-significant increased risk of acquisition among 233 
DMPA users relative to non-HC users [37,48,50]; the direction of effect varies by the reporting 234 
period in one study but remains non-significant [50]. An additional study documented a hazard 235 
ratio close to one among women who reported DMPA at any fourth month visit relative to non-236 
DMPA users [52]. Only one study compared norethisterone enanthate (Net-En) users to non-HC 237 
users, and found a non-significant reduced risk of infection [48].  238 
 239 
Six studies examined the incidence of chlamydia among OCP users [21–23,37,51,52], only one 240 
study specified combined or progestin-only pill use [23]. Three studies documented significant 241 
evidence of increased risk [21,23,37]. One study among HIV-negative women engaging in sex 242 
work in Rwanda compared OCP users to non-HC users (aOR: 6.13, 95%CI: 1.5, 23.8) [37]. Results 243 
from this study are based on few incident cases. The two other studies documented significant 244 
increased risk of similar magnitude. One study compared OCP users to women who were 245 
sterilized or using no contraceptive (aHR: 1.80, 95%CI: 1.10, 2.90) [21], the other compared OCP 246 
users to women who were sterilized or using IUD (aHR: 1.73, 95%CI: 1.08, 2.77) [23].  Three 247 
studies reported null findings. One study did not report the effect coefficient [52], and the 248 
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other found non-significant reduced risk (aHR: 0.2, 95%CI: 0.0, 1.7), among OCP users relative 249 
to non-HC users [51]. 250 
  251 
Gonorrhea  252 
We found no significant prospective evidence that injectable use (five studies) [21,22,37,48,50], 253 
was associated with risk of gonorrhea.  Only one of four studies of OCP use showed increased 254 
the risk of gonorrhea [21–23,37] (Table 4, Figure 4).  Of the three studies which compared 255 
injectable users to non-HC users, two studies found non-significant evidence of increased risk 256 
among DMPA users [48,50], one found non-significant evidence of reduced risk among Net-En 257 
users [48], and one study found non-significant evidence of reduced risk (injectable type 258 
unspecified) [37]. Two additional studies which examined DMPA use relative to women who 259 
were sterilized or used no contraception found an association close to the null [21,22]. One of 260 
these was among women who were living with HIV-1 [22]. Information from the one study 261 
which found increased risk of gonorrhea following OCP use found nearly double risk (aHR 1.7, 262 
95%CI: 1.05, 2.76) among COC users relative to women who used an IUD or were sterilized  263 
[23]. This was the only study to assess pill formulation and found that a higher ratio of 264 
progestin in COC had a nonsignificant, but positive correlation with the risk of gonorrhea 265 
acquisition. The other three studies evaluating OCP use found results in mixed directions and 266 
did not specify pill type. 267 
 268 
Combined STI  269 
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Two studies evaluated a combined group of women who tested positive for either C. 270 
trachomatis or N. gonorrhoeae due to small sample sizes (Table 5) [25,55]. A study among 271 
American STI patients found significant increased risk among DMPA users (aHR: 3.6, 95%CI: 1.6, 272 
8.5), and non-significant increased risk among COC users (aHR: 1.5, 95%CI: 0.6, 3.5) relative to 273 
non-HC users [25]. The second study was among HIV-1 positive women on antiretroviral 274 
therapy was unable to evaluate OCP use due to no incident infections among users. However, 275 
women who used DMPA had more than five times the incident risk of N. gonorrhoeae or C. 276 
trachomatis (combined) (aOR: 5.83, 95%CI: 0.90, 37.7), relative to non-HC users [55].   277 
 278 
Syphilis 279 
Two studies assessed HC use on syphilis incidence (Table 6), both which found non-significant 280 
results. One study found non-significant evidence of increased risk among Kenyan women who 281 
engaged in commercial sex work and used OCPs (aHR: 0.40, 95%CI: 0.10, 1.50) and DMPA (aHR: 282 
0.50, 95%CI: 0.20, 1.40), relative to women who used no contraception or were sterilized [21]. 283 
The other study found non-significant evidence of increased risk among HIV-negative sex 284 
workers in Rwanda who used any injectable relative to non-HC users (aOR: 1.43, 95% CI: 0.11, 285 
19.1) [37]. The finding, however, is based on only four incident cases.  286 
 287 
Trichomoniasis 288 
Studies of HC use on risk of trichomoniasis suggest injectables and OCPs are associated with 289 
reduced risk while findings are mixed regarding implant use (Table 7, Figure 5) 290 
[21,24,34,37,46,48–50]. 291 
 15 
 292 
All seven studies that measured incident trichomoniasis suggest that injectable use reduced 293 
incidence by a magnitude ranging from 0.35 (95%CI: 0.12, 1.01) to 0.70 (95%CI: 0.50, 1.0), 294 
though some results were not statistically significant. Three studies found significant reduced 295 
risk following injectable use (two specified DMPA and one was unspecified) [21,34,46] and two 296 
documented reduced risk that approached significance (one specified DMPA, one was 297 
unspecified but DMPA use was most common) [37,48]. Two of the studies which documented 298 
significant evidence of reduced risk compared HIV-1 negative injectable users (type unspecified) 299 
to non-HC users (aHR: 0.60, 95%CI: 0.47, 0.78), and DMPA users (aHR: 0.60, 95%CI: 0.4, 1.0, 300 
p=0.04) to women who were sterilized or did not use contraception [21,34]. The third study 301 
found women in Uganda who reported DMPA use in the past 12 months were at decreased risk 302 
compared to women who used neither HC nor condoms (aIRR: 0.54, 95%CI: 0.30, 0.98) [46]. 303 
Notably, the same study found non-significant findings of a similar magnitude among women 304 
who reported consistently using only DMPA at baseline and follow-up (aIRR: 0.59, 95%CI: 0.28, 305 
1.26). Only one study reported results for Net-En relative to non-HC use and found non-306 
significant reduced risk [48]. 307 
 308 
Six of seven studies that assessed OCP use and trichomoniasis documented reduced risk, 309 
although only two were significant. One significant finding was reported in a study among OCP 310 
users in five countries (Malawi, South Africa, the United States, Zambia and Zimbabwe) who 311 
were significantly less likely to acquire T. vaginalis relative to non-HC users (aHR: 0.64, 95%CI: 312 
0.47, 0.89) [34]. The other was among OCP using women attending a STI clinic in the U.S. 313 
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relative to those who used IUD or were sterilized (aHR: 0.56, 95%CI: 0.39, 0.81) [24]. Only one 314 
study specified COC use [46]. This study documented null findings among women in Uganda 315 
who reported COC use in the past twelve months (aIRR: 1.02, 95%CI: 0.40, 2.59), or consistently 316 
using COCs in the past 12 months (aIRR: 1.07, 95%CI: 0.25, 4.56) relative to no method (neither 317 
hormonal nor condom). 318 
 319 
One of three studies which assessed implant use on incident trichomoniasis found a three-fold 320 
increased risk of trichomoniasis (aIRR: 3.01, CI: 1.07, 8.49) among Norplant users relative to 321 
women who used no contraception method (hormonal or condoms) and slightly higher risk 322 
among consistent users of Norplant for 12 months (aIRR: 3.13, 95% CI: 1.08, 9.07) [46]. The two 323 
remaining studies found no relationship between implant use (type unspecified) and 324 
trichomoniasis [34,49].  325 
 326 
 327 
Discussion 328 
Among studies of sufficient quality, DMPA use is consistently associated with a reduced risk of 329 
T. vaginalis acquisition, with evidence of substantial (two times or higher) increased risk of HSV-330 
2 incidence from a smaller number of studies. The results for HPV, chlamydia, gonorrhea and 331 
syphilis were inconclusive. Net-En was only assessed in one study [48]. Data on OCP use suggest 332 
reduced incidence of trichomoniasis, with inconclusive findings for HPV, HSV-2, chlamydia, 333 
gonorrhea and syphilis. Implant use was less studied (n=3), and only one specified type 334 
(Norplant). This study documented increased risk of trichomoniasis, but did not assess other 335 
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STIs [46]. Only one study assessed the levonorgestrel IUD and found a higher risk of HR-HPV 336 
incidence compared to the copper IUD; however, findings were marginally significant [39]. 337 
 338 
Findings from our study differ somewhat from two previous systematic reviews, which found 339 
inconclusive results for DMPA and OCPs on incident trichomoniasis, and increased risk of 340 
incident chlamydia [15,16]. However, one previous review primarily synthesized cross-sectional 341 
research [16]. In the second review, half of the studies (2 of 4 for trichomoniasis; 3 of 6 for 342 
chlamydia) did not include statistical adjustment for confounding [15]. Those studies that 343 
reported adjusted T. vaginalis analyses also found decreased risk [21,24]. Prior prospective 344 
evidence of incident HPV from four studies [26–28,31] also suggest mixed results regarding the 345 
influence of OCPs and DMPA [26],Figure without clear trends by HPV type or exposure time.  346 
 347 
This review provides limited evidence that DMPA is associated with increased risk of HSV-2; we 348 
identified no prior review of HC use on incident HSV-2. Notably, our findings are based on a 349 
small number of studies. However, findings correspond with studies in mice which show 350 
heightened susceptibility to HSV-2 following prolonged (>2 weeks) treatment with DMPA 351 
[56,57]. These findings align with the one study that examined multiple exposure periods to 352 
DMPA and found a two-fold increased risk of HSV-2 in consistent DMPA users relative to non-353 
HC users but not among those who initiated, or discontinued use [35]. A recent study in mice 354 
demonstrated that both DMPA and levonorgestrel, another progestin, increase mucosal 355 
epithelial permeability by acting on epithelial cell junction proteins (DSG1α), enhancing access 356 
of inflammatory and infectious viral molecules to the genital tissue, a possible biological 357 
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mechanism [7].  Given substantial evidence that HSV-2 increases risk of HIV infection, [58] if the 358 
finding that DMPA increases the risk of HSV-2 is substantiated, this could be a mechanism for 359 
the association between DMPA use and HIV acquisition. 360 
 361 
Further prospective research is warranted in several areas. Very few studies have explored the 362 
prospective association between HC use and syphilis (n=3) or HSV-2 (n=4) incidence. Similarly, 363 
few prospective studies have explored the potential risk of Net-En (n=1), levonorgestrel IUD 364 
(n=1) or implants on STIs (n=3), while use of these methods is increasing [59]. No reviewed 365 
studies evaluated Sayana Press, the Nuva Ring, or patch. Current large-scale prospective studies 366 
of HIV risk among women should incorporate well measured contraceptive use and STI 367 
outcomes to help address these gaps. Further many of the studies of OCPs did not differentiate 368 
between combined or progestin-only OCPs and similarly some injectable studies did not 369 
differentiate between Net-En and DMPA.  Given that biological responses to HC differ by class 370 
of drug as well as drug formulations,[5] future research needs to distinguish between HC 371 
formulations when estimating risk of STI/HIV acquisition.   372 
 373 
This updated systematic review of prospective evidence published between 2009 and 2017 374 
suggests that DMPA and OCP use are associated with a reduced risk of incident trichomoniasis, 375 
with evidence of increased substantial risk of HSV-2 acquisition with DMPA use from a small 376 
number of studies. Our review findings are tempered by notable methodological limitations. 377 
Prospective evidence regarding the STI risk of hormonal contraceptive methods are extremely 378 
limited or non-existent, highlighting an urgent research need.   379 
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Table 1. Prospective associations between hormonal contraceptive use and Human Papillomavirus (HPV) (N=13). 
Study N, study sample Length of follow-
up; frequency STI 
assessment 
STI diagnostic test Covariates Reference 
Group 
OCPa Injectable IUD or 
Combined 
HC 
Borgdorff, 
2015 [37] 
166, HIV negative sex 
workers in Kigali 
Rwanda ages 18-49; 
N=47 incident HPV (any 
type) cases 
24M; 0M, 6M, 24M Linear Array HPV genotyping 
test (Roche) 
 
 
 
Age, education, years 
worked as sex 
worker, breast-
feeding, consistent 
condom use, 
antibiotic use past 14 
d, ever used 
antibiotics, time 
between assessments 
Non-
pregnant 
non-
hormonal 
user 
OCP on HPV (any 
type) aOR: 1.08 
(0.21, 5.44) 
HPV (any 
type) 
Injectable 
(any typeb) 
aOR: 0.79 
(0.34, 1.83) 
NA 
Harris, 
2009 [36] 
257, HIV negative 
women with no history 
of cervical neoplasia in 
the United States 
seeking routine care at 
family planning clinics, 
ages 18-50; N=152 
cases, N=107 controlsc 
Median follow-up: 
60D; 0M, and 
colposcopy biopsy 
visit 
PCR amplification, line blot 
assay (Roche) and histology 
assessment  
Age at colposcopy-
biopsy, lifetime 
number of male 
partners, and parity  
Cases: 
women with 
positive 
oncogenic 
HPV type; 
Controls: 
HPV-negative 
women with 
negative 
histology and 
cytology at 
both visits: 
HC reference 
group: never 
user of 
specific 
method   
Oncogenic HPV 
COC recent user: 
aOR: 0.6 (0.3, 
1.5); COC ≥1Yr: 
aOR: 0.8 (0.3, 
2.0); <1Yr: aOR: 
0.5 (0.2, 1.2); 
COC former user 
aOR: 0.9 (0.3, 
2.3) 
Oncogenic 
HPV DMPA 
recent userd 
aOR: 1.6 
(0.7, 3.7); 
≥1Yr 
DMPA: aOR: 
4.7 (1.4, 
15.8)*; <1Yr 
DMPA user: 
aOR: 0.7 
(0.3, 2.1); 
Former 
DMPA userd 
aOR: 1.3 
(0.6, 3.1) 
NA 
Gosvig, 
2013 [38] 
604, women with CIN2 
or worse at four 
hospitals in Denmark, 
age range NR; N=18 
cases of reappearance 
(2.2%) 
8-12M follow-up 
duration; 4-6M; 8-
12M 
Hybrid Capture 2; HPV 
genotype testing via line 
probe assay (INNO LiPAv2 
Innogenetics) 
Age, HPV viral load at 
baseline, condom use 
since last visit, # 
partners since last 
visit, time since last 
visit 
 
Non-user of 
oral 
contraception 
in last 4-6M 
OCP on re-
appearance of 
any HPV: aOR 
1.00 (0.21, 4.82) 
NA NA 
Lekovich, 
2015 [39] 
302, HIV negative 
women with IUD 
placement between 
2005 and 2012 and 
Mean time b/w 
pre-IUD and post 
IUD HR-HPV test: 
555 days (Copper 
Hybrid Capture 2 test 
 
Study groups 
matched on: age, 
high-risk HPV 
infection, rate of 
Non-
pregnant 
Copper IUD 
user 
NA NA HR-HPV: 
Levonorgestrel 
vs. Copper IUD 
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Study N, study sample Length of follow-
up; frequency STI 
assessment 
STI diagnostic test Covariates Reference 
Group 
OCPa Injectable IUD or 
Combined 
HC 
pre/post insertion HPV 
testing at participating 
U.S. institution, Mean 
age 33; N=8 /152 cases 
Levonorgestrel IUD, 
2/150 cases Copper IUD 
IUD), 534 days 
(Levonorgestrel 
IUD); IUD 
placement and 
repeat HR-HPV 
test: 356 (Copper 
IUD), 349 
(Levonorgestrel 
IUD) 
abnormal cytology 
and proportion of 
smokers 
OR: 4.11, 
p=0.056 
Louvanto, 
2011 [40] 
255, postpartum 
women in Finland, 
Mean age 26 (SD 3.1); 
N=203 incident cases, 
133 for HPV- species α7 
and α9 included in 
analyses  
6Y; 0M, 2M, 12M, 
24M, 36M, 6Y 
Multiplex-HPV genotyping kit 
(Progen Biotechnik GmbH)  
 
 
Age, HR-HPV 
seropositive at 
baseline, 
seroconverted to HR-
HPV, # sexual 
partners until age 20, 
lifetime # sex 
partners, age 
initiation of OC use, 
marital status, 
employment status, 
age of onset of sexual 
activity, baseline PAP 
smear results, 
baseline oral HR-HPV 
DNA status, 
frequency of sex, # of 
births, oral sex, ever 
had STD, history of 
genital warts, history 
of oral warts, age 
initiation of smoking, 
pregnancy during 
follow-up, change in 
marital status during 
follow-up 
 
Final model (empirical 
strategy): age, 
seroconverted to HR-
Never used 
OC pills 
OCP (ever use) 
on Species α7 
and α9 HR- HPV: 
aIRR: 
 (ns) NR 
(respectively) 
NA NA 
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Study N, study sample Length of follow-
up; frequency STI 
assessment 
STI diagnostic test Covariates Reference 
Group 
OCPa Injectable IUD or 
Combined 
HC 
HPV, # sexual 
partners until age 20, 
lifetime # sexual 
partners, age initiated 
OC use, smoking, 
pregnancy during 
follow-up, change in 
marital status during 
follow-up 
Marks, 
2011 [41] 
1135, HIV-negative 
women ages 20-37 in 
Thailand, reporting no 
commercial sex work in 
past 6M and willing to 
adhere to self-selected 
contraceptive method 
for at least 1Y; N=269 
(8%) incident cases for 
any HPV, 157 (4.7%) 
incident HR-HPV cases 
18M; 0M, 6M, 
12M, 18M 
QIAamp DNA Blood Kit 
(Qiagen), HPV Linear Array, 
PCR assay (Roche Diagnostics) 
 
Age, study site, # live 
births, male condom 
use P6M, age sexual 
debut, # lifetime 
partners, # partners 
P6M, smoking P6M, 
cervical cytology at 
enrollment and 
follow-up, BV at 
enrollment, prior STI 
infection, cervical 
ectopy 
 
Final model (empirical 
strategy): age, study 
site, # of lifetime and 
recent sexual 
partners, new sexual 
partner, concurrent 
BV, duration of HC 
use 
Non- 
hormonal 
user during 
same interval 
of 
assessment 
COC on HPV (any 
type) aOR: 1.27 
(0.93, 1.74); HR-
HPV aOR: 1.22 
(0.81, 1.83) 
DMPA on 
HPV (any 
type) aOR: 
0.90 (0.63, 
1.31), HR-
HPV aOR: 
0.87 (0.55, 
1.35) 
NA 
Moscicki 
2001 [26] 
105, women aged 13 to 
21 attending 2 family 
planning clinics in San 
Francisco, USA; N=54 
incident cases  
Median follow-up: 
50M [IQR: 23-
79M]; ~4-6M (9 
median visits, IQR: 
4-15) 
PCR assay; B-globin control; 
dot blot and Roche reverse 
blot method (Roche 
Molecular Systems) 
 
Rate of new partners 
per month since last 
visit, history of HSV, 
history of vulvar 
warts, lifetime sexual 
partners, marijuana 
use 
 
Non-current 
OCP user 
OCP on HPV (any 
type) aHR 0.49 
(0.28, 0.86)* 
NA NA 
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Study N, study sample Length of follow-
up; frequency STI 
assessment 
STI diagnostic test Covariates Reference 
Group 
OCPa Injectable IUD or 
Combined 
HC 
Final model: rate of 
new partners per 
month since last visit, 
history of HSV, history 
of vulvar warts. 
Nielsen, 
2009 [42] 
6246, women aged 20-
29 in Copenhagen, 
Denmark, randomly 
sampled from general 
population; N= 798 
(12.8%) HR-HPV incident 
cases 
2Y; 0M and 2Ye 
 
 
Hybrid Capture 2 and LiPA V2 
PCR assay (Innogenetics); B-
globin control 
 
 
Age, # sexual 
partners, marital 
status, self-reported 
history of chlamydia, 
self-reported history 
of genital warts, 
parity, current 
condom use, amount 
of smoking  
 
Final model (empirical 
strategy): age, # of 
sexual partners 
during follow-up, 
marital status, 
interaction between 
marital status and 
number of sexual 
partners during 
follow-up 
Current non- 
hormonal 
user  
OCP on HR-HPV: 
≤2Yr aOR: 1.01 
(0.68, 1.50), 3-
4Yr aOR: 1.39 
(0.98, 1.99); 5-
6Yr aOR: 1.44 
(1.00, 2.07); 7+Yr 
aOR: 1.66 (1.17, 
2.35)*, Per Yr): 
1.04 (0.98, 1.10) 
 
NA NA 
Phelan, 
2009 [43] 
220, HIV+ and HIV 
women ages 18+ who 
reported injection drug 
use in past 10 years in 
Baltimore, USA; Mean 
age 37 (SD 6.6); 
Detection of new type-
specific HPV cases 22% 
of 775 visits 
5Y; 0M and every 
6M 
PCR assay; B-globin controls, 
oligonucleotide dot blot 
hybridization 
  
Age, HIV status and 
CD4 category, 
smoking in P6M, 
injection drug use 
P6M, marijuana use 
P6M, any STD P6M, # 
male sex partners 
P6M, # male sex 
partners P10Y, # live 
lifetime births 
 
Final model (empirical 
and theoretical 
approach): age, HIV 
Never user of 
OC (lifetime) 
OCP (ever): Not 
significant at 
univariate level 
(among HIV+ or 
HIV- women) so 
multivariate not 
reported 
NA NA 
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Study N, study sample Length of follow-
up; frequency STI 
assessment 
STI diagnostic test Covariates Reference 
Group 
OCPa Injectable IUD or 
Combined 
HC 
status and CD4 level, 
crack use in P6M, # of 
male sex partners in 
P10Y 
Sellors, 
2003 [28] 
253, Canadian women 
ages 15 to 49 
in selected physician 
practices; 28 incident 
HPV cases (11.1%) 
1Y; 0M and 12M PCR assay with HPV-
genotyping; HCII assay for HR-
HPV detection 
Age, median number 
of sex partners in the 
last year, median 
number of lifetime 
sex partners, marital 
status, smoking status 
Non-OCP user OCP on HR-HPV 
aOR: 0.70 (0.20, 
2.0) 
NA NA 
Shew, 
2015 [44] 
150, adolescents ages 
14-17 in Indianapolis, 
U.S. visiting one of 3 
primary care clinics 
Mean follow-up: 
5.8Y (3.9-9.2); 
Every 3M 
Linear array HPV genotyping 
test (Roche Diagnostics) and 
PCR assay with B-globin 
control 
 
STIs (clinic test): CT, 
NG and TV; 
contraceptive use, 
condom use, coital 
frequency, number 
of partners 
Non-user of 
OCP in last 
3M, Non-
user of 
DMPA in last 
3M, 
respectively 
OCP on HPV (all 
types) aHR: 2.0 
(1.28, 3.15)*; 
HR-HPV aHR: 
1.31 (0.73, 
2.35); LR-HPV 
aHR: 2.73 (1.52, 
4.90)* 
 
DMPA on 
HPV (all 
types) aHR: 
0.96 (0.67, 
1.38); HR-
HPV aHR: 
0.80 (0.54, 
1.19); LR- 
HPV aHR: 
1.57 (0.90, 
2.75) 
NA 
Winer, 
2003 [27] 
553, university women 
in Seattle, USA ages 18-
20; incident cases (all 
HPV type) among OCP 
users: 92 per 503 PY vs. 
56/553 PY among non-
OCP users 
5Y; 4M intervals PCR assay and dot-blot 
hybridization with B-globin 
control 
Time interval, current 
smoking, history of 
non-genital warts, 
history of tampon 
use, being delivered 
by cesarean section, 
length of time having 
known a partner, 
partner’s ethnicity, 
partner’s age, 
partner’s educational 
level, partner’s 
lifetime number of 
partners, partner’s 
circumcision status, 
condom use with a 
new partner.  
Non-OCP 
user 
OCP on HPV (all 
types) aHR: 1.40 
(1.01, 1.80)* 
NA NA 
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Study N, study sample Length of follow-
up; frequency STI 
assessment 
STI diagnostic test Covariates Reference 
Group 
OCPa Injectable IUD or 
Combined 
HC 
Whether partner had 
ever had a STI, 
subject/partner 
alcohol use during 
sex. 
 
Final model: no. sex 
partners, condom use 
with new partners, 
sex partner’s no. of 
other partners, new 
partner in past 12 M, 
time knowing partner 
before sex, current 
smoker 
Winer, 
2016 [45] 
420, women aged 25-65 
in the USA sampled 
from internet dating 
group; cumulative 
incidence of HR-HPV: 
25.4% 
Mean follow-up: 
12.5M +/- 5M; 
Mean interval b/w 
assessment: 5.1M 
+/- 1.4M 
PCR assay with B-globin 
controls, Roche Linear Array 
genotyping test 
 
Age at first sex, (time 
dependent variables): 
age, marital status, 
smoking history, 
abnormal PAP history, 
current HC use, 
menopausal status, 
sex with ≥1 male 
partner in past 6M, 
lifetime # sex partners 
 
Final model (empirical 
strategy): lifetime # of 
male sex partners, 
and male sex partners 
in the P6M (women 
with ≥1 partner in 
P6M)   
Current non-
hormonal 
user  
NA NA Any HC use on 
HR-HPV, all 
women aHR: 
1.82 (1.17, 
2.83)*; 
Women with 
no sex 
partners in 
P6M aHR: 4.16 
(1.27, 13.63)*; 
Women with 
≥ 1 partner in 
P6M aHR: 1.65 
(1.05, 2.59)* 
Notes: PY: person-years at risk; aOR: adjusted odds ratio; aHR: adjusted hazard ratio. HR-HPV: high-risk HPV, LR-HPV: low-risk HPV. *p<0.05; #p=0.056;  
a OCP type was unspecified unless COC (combined oral contraception) or POP (progestin-only pill) is noted.  
b Injectable type not reported but authors note most commonly DMPA in setting with occasional norethisterone enanthate (NE-ENT) use. 
c Case control study. 
d Former user defined as having stopped using method at least one year before colposcopy-biopsy. Recent use defined as having used that method within 6 months of biopsy. 
e Contraceptive use exposure period retrospectively recalled, exceeds study follow-up duration. 
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Table 2. Prospective associations between hormonal contraceptive use and herpes simplex virus type 2 (HSV-2) (N=4).  
Study N, study 
sample 
Length of 
follow-up; 
frequency 
STI 
assessment 
STI 
diagnostic 
test 
Length of 
follow-up; 
frequency 
STI 
assessment 
Covariates Reference 
group 
OCPa Injectable Combined 
HC 
Borgdorff, 
2015 [37] 
163, HIV-
negative sex 
workers in 
Kigali, Rwanda 
ages 18 to 49, 
N=21 HSV-2 
incident casesc 
24M; 0M, 
3M, 6M, 
12M, 24M 
 
HerpeSelect 2 
ELISA (index 
≥3.5 defined 
as positive) 
24M; 0M, 
3M, 6M, 
12M, 24M 
 
 
Age, education, years worked 
as sex worker, breast-feeding, 
consistent condom use, 
antibiotic use past 14 d, ever 
used antibiotics, time duration 
between assessments 
Non-
pregnant 
non-
hormonal 
user 
OCP aOR: 
4.28 (0.07, 
262.1) 
Injectable (type 
not specifiedd) 
aOR: 6.34 (0.25, 
158.5) 
 
NA 
Chohan, 
2009 [53] 
297, HIV-
negative sex 
workers in 
Mombasa, 
Kenya ages 18 
to 46, N=115 
HSV-2 incident 
cases (23 cases 
per 100 PY)b 
 
 
13Y; every 
1M (median 
time b/w 
visits: 33d 
[IQR 28-48] 
 
HSV-2- type-
specific HSV-2 
gG based 
ELISA (index 
value of >1.1 
defined as 
positive) 
 
13Y; every 
1M (median 
time b/w 
visits: 33d 
[IQR 28-48] 
 
 
Education, parity, alcohol and 
tobacco use, vaginal washing 
practices, bar vs. night club 
work. Time-dependent 
variables: age, duration of sex 
work, presence of other genital 
tract infections, # sex partners 
per week, condom use during 
past working week 
 
Final model: duration of sex 
work, bar (vs. night club) work, 
# sex partners per week, 
percentage condom use past 
week, presence of BV  
Non-
hormonal 
user  
OCP aHR: 
0.50 (0.23, 
1.08)# 
NA aHR 
Norplant/ 
DMPA 
(combined): 
0.92 (0.53, 
1.61) 
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Study N, study 
sample 
Length of 
follow-up; 
frequency 
STI 
assessment 
STI 
diagnostic 
test 
Length of 
follow-up; 
frequency 
STI 
assessment 
Covariates Reference 
group 
OCPa Injectable Combined 
HC 
Grabowski, 
2015 [35] 
682, HIV-
negative 
women in Rakai, 
Uganda ages 15 
to 49 who had a 
HIV-negative 
male partner, 
N=52 HSV-2 
incident casese 
3Y; 0M, 12M 
& 24M 
 
HSV-2 ELISA 
test 
3Y; 0M, 12M 
& 24M 
 
Age, education of woman and 
male partner, # of lifetime 
sexual partners. Time-varying 
variables: male circumcision, 
coital frequency, and female 
and male self-report of any 
condom use and non-marital 
partners in the past year.  
 
Final model: did not include 
coital frequency or male 
circumcision based on model 
fit 
Non-
pregnant 
non-
hormonal 
user  
OCP aHR: 
0.49 (0.08, 
3.01) 
Consistent 
DMPA users 
aHR: 2.26 (1.09, 
4.69)*; Initiated 
DMPA aHR: 0.75 
(0.29, 1.92); 
Discontinued 
DMPA use aHR: 
0.58 (0.13,2.51) 
NA 
Socias, 
2017 [54] 
149, HIV-
positive (N=13) 
and HIV-
negative 
(N=136) sex 
workers in 
Vancouver, 
Canada ages 
14+, N=39 HSV-
2 incident cases; 
17.1 cases per 
100 PY (12.4, 
23.6) 
 
4Y; every 4M 
 
Serum 
samples via 
non-specific 
EIA HSV IgG. 
If reactive, 
anti-HSV-2 
using TSS 
Focus 
HerpeSelect-
2 IgG EIA 
(Focus 
Diagnostics) 
 
4Y; every 4M 
 
 
Time invariant: Age, indigenous 
ancestry, education. Time-
varying: HIV status, incident 
STIs (T. pallidum, NG and CT), 
average # of clients per week, # 
male non-commercial partners, 
inconsistent use of condoms by 
clients and non-clients, 
respectively, type of sex work 
venue 
 
Final model (stepwise 
selection): type of sex work 
venue 
Non-DMPA 
user in prior 
6M 
NA HIV positive and 
negative DMPA 
users aHR: 4.43 
(1.90, 10.35)*; 
HIV negative 
DMPA users 
aHR: 3.97 (1.64, 
9.60)* 
 
NA 
Notes: PY: person-years at risk. * Statistically significant at p<0.05. # Marginally significant at p=0.08; 
a OCP type was unspecified unless COC (combined oral contraception) or POP (progestin-only pill) is noted. 
b 10 women seroconverted to HSV-2 & HIV-1 at same visit; PY: person-years; NA: not assessed by study. 
c Women censored after first incident infection. 
d Injectable type not reported but authors note most commonly DMPA in setting with occasional norethisterone enanthate use. 
e Excluding incident cases among pregnant women. 
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Table 3. Prospective associations between hormonal contraceptive use and Chlamydia trachomatis (CT) (N=9). 
Study N, study sample, N of 
incident cases or 
incident rate 
Length of 
follow-up; 
frequency STI 
assessment 
STI Diagnostic 
test 
Covariates  Reference 
group 
OCPa Injectable Implant 
Borgdorff, 
2015 [37] 
397, HIV-negative sex 
workers in Kigali, Rwanda 
ages 18-49; N=30 incident 
casesb,e 
12M; 0M, 6M, 
12M 
 
 
Endocervical 
swabs via 
Amplicor CT/NG 
PCR test (Roche 
Diagnostics) 
 
Age, education, years worked as 
sex worker, breast-feeding, 
consistent condom use, antibiotic 
use past 14 d, ever used 
antibiotics, time duration 
between assessments 
Non-pregnant 
non-hormonal 
user  
OCP aOR: 6.13 
(1.5, 23.8)* 
Injectable 
(type not 
specifiedd) 
aOR:  2.24 
(0.69, 7.29) 
 
NA 
Baeten, 
2001 [21] 
948, HIV-1 negative sex 
workers in Mombasa, 
Kenya ages 16-48; N=175 
incident cases (11.1/100 
PY) 
Range 15 to 
2366 days 
(median: 421 
days); median 
time b/w visits: 
35 days 
Enzyme-linked 
immunoabsorbe
nt assay (ELISA) 
(Microtrak) 
Age, years of education, years of 
prostitution, parity, number of 
sexual partners, place of work (ie, 
bar vs. nightclub), number of 
sexual contacts, and condom 
usage 
No 
contraceptives 
or tubal 
ligation 
OCP aHR: 1.8 
(1.1, 2.9)* 
DMPA aHR: 1.6 
(1.1, 2.4)* 
NA 
Kapiga, 
2009 [47] 
958, HIV negative women 
ages 16 to 62 in Lusaka, 
Zambia (ZA), Moshi 
Tanzania (TZ) and 
Durban/Hlabisa, South 
Africa (SA); Incidence rate 
b: 19.5/100 PYAR (SA); 
4.9/100 PYAR (TZ, ZA) 
 
12M, every 3M 
 
 
TZ/ZA site: 
endocervical 
swabs via 
enzyme-linked 
immunosorbent 
assay (ELISA), 
(Murex 
Biotech); SA 
site: urine 
samples via BD 
Probe Tec ET 
assayc  
 
 
Age, site, partner earns income, # 
sex partners, frequency vaginal 
sex in past 1W, anal sex in past 
3M, other STIs, bacterial 
vaginosis, candida, abnormal 
vaginal discharge on exam, 
abnormal cervical discharge on 
exam, incident HIV  
 
Final model (empirical approach): 
site, age, # sex partners, incident 
HIV infection and N. gonorrhoeae 
infection (SA model); site, 
presence of candida and 
abnormal vaginal discharge on 
exam (TZ/ZA model) 
Not specified OCP 
Durban/Hlabis
,SA aOR: NR 
(ns); Moshi 
TZ/Lusaka ZA 
site aOR: NR 
(ns) 
DMPA 
Durban/Hlabis,
SA aOR: 1.8 
(1.0, 3.3)*; 
DMPA Moshi 
TZ/Lusaka ZA 
site aOR: NR 
(ns) 
 
Norplant 
Durban/Hlabis,S
A aOR: NR (ns); 
Norplant Moshi 
TZ/Lusaka ZA 
site aOR: NR (ns) 
 
Louv, 
1989 [23] 
818, U.S. women ages 19 
to 29 attending a STI clinic 
in Birmingham Alabama; 
N=214 incident cases b  
6M; Monthly Fluorescein-
tagged 
antibody; 
Microtrak 
Culture 
confirmation 
(Syva CO) 
Age, mean number of sex acts 
per month, mean number of 
partners during follow-up period, 
parity, gravidity 
Tubal ligation 
or IUD user 
COC: aHR: 
1.73 (1.08, 
2.77)* 
 
 
NA NA 
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Study N, study sample, N of 
incident cases or 
incident rate 
Length of 
follow-up; 
frequency STI 
assessment 
STI Diagnostic 
test 
Covariates  Reference 
group 
OCPa Injectable Implant 
Lavreys, 
2004  [22] 
242, HIV-1 positive 
commercial sex workers 
attending STI clinic in 
Mombasa, Kenya; N=26 
incident cases, incidence 
rate: 7.7/100 PY 
Median follow-
up 35M (IQR: 
11-62M); Every 
1M 
Antigen test by 
ELISA 
(Microtrak, 
Syva) 
Age, years of education, years of 
sex work, parity, workplace, 
number of sexual partners per 
week, condom use 
No 
contraception 
or tubal 
ligation 
OCP: aHR 2.20 
(0.70, 7.30) 
DMPA: aHR 
3.10 (1.0, 9.4)# 
NA 
Masese, 
2013 [51] 
 
865, HIV positive and HIV-
negative women who 
report engaging in 
transactional sex, ages 18 
to 50 in Mombasa, Kenya; 
N=101 incident casesb, 
incidence rate = 5.0/100 
PY 
4Y, every 1-3M 
 
 
Endocervical 
swab via  
Gen-Probe 
Aptima GC/CT 
Detection 
System 
Age, vaginal microbiota, place of 
work (bar vs. nightclub or home 
based/ other), educational level, 
marital status, unprotected 
intercourse in past wk, # of sex 
partners in past wk, vaginal 
washing, presence of other 
genital tract infections (T. 
vaginalis, C. albicans, N. 
gonorrhoeae), HIV-1 serostatus, 
and cervical ectopy 
 
Final model (empirical approach): 
Age, unprotected sex with >1 sex 
partner in past week, HIV status, 
N. gonorrhoeae infection 
Non-hormonal 
user  
OCP aHR: 0.2 
(0.0, 1.7) 
DMPA aHR: 1.8 
(1.1, 3.0)* 
 
 
NA 
Pettifor, 
2009 [48] 
567, HIV-negative women 
ages 18 to 40 recruited 
from family planning 
clinics in Orange Farm, 
South Africa; N=119 
incident cases b, incident 
rate: 28.2 per 100 PY 
1Y; every 3M 
 
  
Urine sample via 
ligase chain 
reaction (LCx®; 
Abbot 
Laboratories) 
 
Age, relationship status, 
education, frequency of sex in 
the past 3M, # partners in the 
past 3M, condom use in the past 
3M, vaginal douching past 3M, 
age of first sex  
 
Final model (empirical and 
theoretical approach): Age, 
education, condom use 
consistency in past 3M 
Non- pregnant, 
non-hormonal 
user 
NA DMPA aIRR: 
1.24 (0.80, 
1.94); NET-EN 
aIRR: 0.91 
(0.59, 1.43) 
NA 
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Study N, study sample, N of 
incident cases or 
incident rate 
Length of 
follow-up; 
frequency STI 
assessment 
STI Diagnostic 
test 
Covariates  Reference 
group 
OCPa Injectable Implant 
Romer, 
2013 [50] 
342, adolescent girls ages 
14-17 attending clinics in 
inner-city areas of 
Indianapolis, USA; N=165 
incident cases b 
Originally 27M, 
extended to 5Y 
for some 
participants; 
every 3M 
 
Clinician 
obtained 
cervical samples 
or self-obtained 
vaginal swabs 
via nucleic acid 
amplification 
tests (NAATs)  
(Amplicor PCR, 
Roche 
Diagnostics) 
Age, positive STI test at start of 
period, # of partners in past 3M, 
# of lifetime partners, # of sexual 
events in last 3M (diary period), # 
of unprotected sexual events in 
last 3M (diary period) 
 
Non-hormonal 
user 
NA DMPA, use in 
past 3M aOR: 
0.76 (0.45, 
1.31); DMPA 
used 3-6M ago 
aOR: 1.17 
(0.69, 1.96) 
NA 
Russell, 
2016 [52] 
225, HIV-negative women 
recruited from outpatient 
clinics ages 15-35 who 
had lower genital tract 
infection or were 
biologically at risk of STI 
infection from Pittsburgh 
PA, USA; Incidence rate: 
48 women tested positive, 
28 per 100 PYc incident 
rate 
 
Median 12M 
FU; 0M, 1M, 
4M, 8M, 12M 
 
Endocervical 
swab via 
nucleic acid 
amplification 
tests (NAATs) 
Age, education, site of C. 
trachomatis (CT) infection at 
enrollment (cervix vs. 
cervix/endometrium, or 
uninfected), GN infection during 
follow-up, STI diagnosis among 
partner during follow-up, # of 
male partners since last visit, new 
male partners since last visit, sex 
with uncircumcised male in last 
3M, condoms (reported at any 
visit) 
 
Final model (empirical approach): 
age, N. gonorrhoeae during 
follow-up, site of CT infection, CT 
infection by partner during 
follow-up, new male partner 
since last visit, sex with 
uncircumcised male last 3M 
Non-user of 
OCP or DMPA, 
respectively 
OCP aHR: NR 
(ns) 
DMPA aHR: 
1.03 (0.59, 
1.78) 
 
NA 
Notes: PY: person-years at risk. * Statistically significant at p<0.05. # p=0.05 
a OCP type was unspecified unless COC (combined oral contraception) or POP (progestin-only) is noted.  
b Multiple incident cases per woman were allowed, i.e., incident cases defined as a positive test following a negative test. 
c Incident infection defined as any positive test during follow-up. 
d Injectable type not reported but authors note most commonly DMPA in setting with occasional norethisterone enanthate (NE-ENT) use. 
e Excluding cases among pregnant women.   
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Table 4. Prospective associations between hormonal contraceptive use and Neisseria gonorrhoeae (NG) (N=7).  
Study N, study sample Length of 
follow-up; 
frequency 
STI 
assessme
nt 
STI 
diagnostic 
test 
Covariates Reference 
group 
OCPa Injectable Implant 
Borgdorff, 
2015 [37] 
381, HIV-negative 
sex workers in 
Kigali, Rwanda 
ages 18 to 49, 
N=42  incident 
cases b,d 
12M; 0M, 
6M, 12M 
 
 
Endocervical 
swab via 
Amplicor 
CT/NG PCR 
test (Roche 
Diagnostics) 
Age, education, years worked as 
sex worker, breast-feeding, 
consistent condom use, 
antibiotic use past 14 d, ever 
used antibiotics, time duration 
between assessments 
Non-pregnant  
non-hormonal 
user 
OCP aOR: 2.57 
(0.78, 8.45) 
Injectable (type 
not specifiedc) 
aOR: 0.80 
(0.28, 2.31) 
 
NA 
Baeten, 
2001 [21] 
948, HIV-1 
negative sex 
workers in 
Mombasa, Kenya 
ages 16-48; N=272 
incident cases 
(16.5/100 PY) 
Range 15 to 
2366 days 
(median: 
421 days); 
median 
time b/w 
visits: 35 
days 
Culture on 
Thayer-
Martin 
media 
Age, years of education, years of 
prostitution, parity, number of 
sexual partners, place of work 
(ie, bar vs. nightclub), number of 
sexual contacts per week, and 
condom usage 
No 
contraception or 
tubal ligation 
OCP aHR: 1.4 
(0.9, 2.1) 
DMPA aHR: 1.1 
(0.8, 1.6) 
NA 
Louv 1989 
[23] 
818, U.S. women 
ages 19 to 29 
attending a STI 
clinic in 
Birmingham 
Alabama; N=155 
incident cases b 
6M; 
Monthly 
Gram stain 
or oxidase 
reagent 
(Marion 
Scientific), 
confirmation 
by Rapid NH 
system 
(Innovative 
Diagnostic 
Systems) 
Age, mean number of sex acts 
per month, mean number of 
partners during follow-up period, 
parity, gravidity 
Tubal ligation or 
IUD user 
COC:  aHR: 1.70 
(1.05, 2.76)* 
NA NA 
Lavreys 
2004 [22] 
242, HIV-1 positive 
commercial sex 
workers attending 
STI clinic  in 
Mombasa, Kenya; 
N=119 incident 
cases, incidence 
rate: 14.9/100 PY 
Median 
follow-up 
35M (IQR: 
11-62M); 
Every 1M 
Antigen test 
by ELISA 
(Microtrak, 
Syva) 
Age, years of education, years of 
sex work, parity, workplace, 
number of sexual partners per 
week, condom use 
No 
contraception or 
tubal ligation 
OCP: aHR 0.6 
(0.3, 1.3) 
DMPA: 1.0 (0.6, 
1.7) 
NA 
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Study N, study sample Length of 
follow-up; 
frequency 
STI 
assessme
nt 
STI 
diagnostic 
test 
Covariates Reference 
group 
OCPa Injectable Implant 
Kapiga, 
2009 [47] 
958, HIV negative 
women ages 16 to 
62 in Lusaka, 
Zambia (ZA), 
Moshi Tanzania 
(TZ) and 
Durban/Hlabisa, 
South Africa (SA), 
Incidence ratea: 
16.5/100 PYAR 
(SA); 5.3/100 PYAR 
(TZ, ZA) 
12M; every 
3M 
 
 
TZ and ZA: 
culture 
methods 
used. SA: 
urine sample 
via BD Probe 
Tec ET assay 
Age, site, partner earns income, 
# sex partners, frequency vaginal 
sex past 1W, anal sex past 3M, 
other STIs, BV, candida, 
abnormal vaginal discharge on 
exam, abnormal cervical 
discharge on exam, incident HIV 
 
Final model (empirical 
approach):  site and incident HIV 
infection (SA model); age (TZ/ZA 
model) 
Not specified OCP 
Durban/Hlabisa 
SA site: aOR: 
NR (ns); Moshi 
TZ/Lusaka ZA 
site aOR: NR 
(ns) 
DMPA 
Durban/Hlabisa 
SA site: aOR: 
NR (ns); Moshi 
TZ/Lusaka ZA 
site aOR: NR 
(ns) 
 
 
Norplant 
Durban/Hlabisa 
SA site: aOR: 
NR (ns); Moshi 
TZ/Lusaka ZA 
site aOR: 4.7 
(1.3, 16.5)* 
 
Pettifor, 
2009 [48] 
567, HIV-negative 
women ages 18 to 
40 recruited from 
family planning 
clinics in Orange 
Farm, South Africa; 
N=45 incident 
cases b incident 
rate: 9.9 per 100 
PY 
1Y; 0M, 
2M, 6M, 
8M and 
12M (NET-
EN users) 
or 0M, 3M, 
6M, 9M 
and 
12M 
(DMPA 
users and 
controls) 
Urine sample 
via 
ligase chain 
reaction 
(LCx®; Abbot 
Laboratories) 
 
Age, relationship status, 
education, frequency of sex past 
3M, # sex partners past 3M, 
condom use past 3M, vagina 
douching past 3M, age of first 
sex  
 
Final model (empirical and 
theoretical approach): Age, 
education and condom use 
consistency in past 3M 
Non-pregnant  
non-hormonal 
user 
NA DMPA aIRR: 
1.30 (0.58, 
2.98); NET-EN 
aIRR: 1.11 
(0.55, 2.25) 
NA 
Romer, 
2013 [50] 
342, adolescent 
girls ages 14-17 
attending clinics in 
inner-city areas of 
Indianapolis, USA; 
N=65 incident 
cases b 
Originally 
27M, 
extended 
to 5Y for 
some 
participants
; every 3M 
 
 
Nucleic acid 
amplification 
tests  
(Amplicor 
CT/NG PCR; 
Roche 
Diagnostics). 
Positive 
results 
confirmed by 
Gen-Probe 
Age, positive STI test at start of 
period, # of sexual partners in 
past 3M, # of lifetime sexual 
partners, # of sexual events in 
last 3M (diary period), # of 
unprotected sexual events in last 
3M (diary period) 
 
Non-hormonal 
user  
NA DMPA use in 
current 3M 
period aOR: 
1.19 (0.57, 
2.48); DMPA 
use in prior 3M 
aOR: 1.12 
(0.54, 2.32) 
NA 
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Notes: PY: person-years at risk. * Statistically significant at p<0.05.  
a OCP type was unspecified unless COC (combined oral contraception) or POP (progestin-only pill) is noted.  
b Multiple incident cases per woman were allowed, i.e., incident cases defined as a positive test following a negative test. 
c Injectable type not reported but authors note most commonly DMPA in setting with occasional norethisterone enanthate use. 
d Excludes cases among pregnant women. 
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Table 5. Prospective associations between hormonal contraceptive use and Chlamydia trachomatis (CT) or Neisseria  
gonorrhoeae (NG) (combined) (N=2).  
Study N, study 
sample 
Length of 
follow-up; 
frequency STI 
assessment 
STI diagnostic 
test 
Covariates Reference 
group 
OCPa Injectable Implant 
Low 2014 
[55] 
172, HIV-1 
positive women 
on antiretrovirals 
who engage in 
transactional sex 
in Bobo-
Dioulasso 
Burkina Faso, 
ages 18 to 50, 
N=11 incident 
cases GN; rate of 
2.76 cases per 
100 PY; 3 incident 
cases CT, rate of 
0.75 per 100 PY b 
4Y; 0M, ~3-6M 
 
Cervical swab 
via PCR 
(Amplicor 
CT/NG PCR 
assay, Roche) 
using pooling 
approach 
Age, education, tobacco use, # 
sex acts past wk, alcohol use, 
sex work, condom use, vaginal 
washing, antibiotic use past 1M, 
abnormal vaginal discharge on 
exam, genital ulcers on exam, 
abnormal cervical exam, genital 
warts, concurrent BV, T. 
vaginalis, Candida albicans, or 
HSV-2 DNA, presence of Y-PCR, 
HIV-1 plasma viral load, HIV-1 
eCVL RNA detected, CD4 count, 
time since sample 
collection, antiretroviral status 
 
Final model (empirical and 
theoretical approach): # sex acts 
past wk, CD4 count, education 
Non-hormonal 
user  
OCP aOR: ns 
(NR)  
DMPA  on 
NG/CT aOR: 
5.83 (0.90, 
37.70) 
NA 
Morrison 
2004 [25]  
819, women 
attending 2 
reproductive 
health clinics in 
Baltimore, USA 
ages 15 to 45. 
N=45 incident 
cases of CT or 
GN; 6.2 per 100 
PY. 
3, 6 and 12M CT by ligase 
chain reaction 
(LCx; Abbott 
Laboratories). 
GN by Gram 
stain, oxidase 
reaction, 
lactamase 
and production. 
Confirmation by 
Gonocheck II (E-
Y Laboratories). 
Age, race, and site and 
measures of contraceptive 
exposure.  
Non-hormonal 
user 
COC aHR: 1.5 
(0.6, 3.5) 
DMPA: aHR: 
3.6 (1.6, 8.5) 
NA 
Notes: PY: person-years at risk. * Statistically significant at p<0.05.  
 a OCP type was unspecified unless COC (combined oral contraception) or POP (progestin-only pill) is noted.  
b Incidence is new cases of NG or CT during study period, divided by number of women at risk; cases at baseline excluded.  
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 Table 6. Prospective associations between hormonal contraceptive use and Treponema pallidum (syphilis) (N=3).  
Study (N), study 
sample 
Length of 
follow-up; 
frequency 
STI 
assessment 
STI diagnostic test Covariates Reference 
group 
OCPa Injectable Implant 
Borgdorff, 
2015 [37] 
354, HIV-negative 
sex workers in 
Kigali, Rwanda 
ages 18 to 49, N=4  
incident cases b 
12M; 0M, 
6M, 12M 
 
 
 
Spinreact Raplid Plasma 
Reagin test, 
confirmation by 
Spinreact T. pallidum 
Haemagglutination test  
Age, education, years worked as 
sex worker, breast-feeding, 
consistent condom use, antibiotic 
use past 14 d, ever used 
antibiotics, time duration 
between assessments 
Non-pregnant 
non-hormonal 
user 
NA Injectable 
(type not 
specifiedb) 
aOR: 1.43 
(0.11, 19.1) 
 
NA 
Baeten, 
2001 [21] 
948, HIV-1 
negative sex 
workers in 
Mombasa, Kenya 
ages 16-48; N=48 
incident cases 
(2.9/100 PY) 
Range 15 to 
2366 days 
(median: 421 
days); median 
time b/w 
visits: 35 days 
Hemagglutination assay 
(Biotech Laboratories) 
Age, years of education, years of 
prostitution, parity, number of 
sexual partners, place of work (ie, 
bar vs. nightclub), number of 
sexual contacts per week, and 
condom usage 
Non-hormonal 
user or tubal 
ligation 
OCP aHR: 
0.40 (0.10, 
1.50) 
DMPA aHR: 
0.50 (0.20 
1.4) 
NA 
Kapiga, 
2009 [47] 
958, HIV negative 
women from 
general 
population ages 
16 to 62 in Lusaka, 
Zambia (ZA), 
Moshi Tanzania 
(TZ) and 
Durban/Hlabisa, 
South Africa (SA), 
Incidence rate b: 
7.5/100 PY (all 
sites) 
 
 
12M; every 
3M 
 
 
Positive serum reaction 
after both a rapid 
plasma reagin card test 
and treponema 
pallidum 
haemagglutination 
assay (TPHA) or 
microhaemagglutination 
assay-treponema 
pallidum (MHA-TP) 
 
Age, site, partner earns income, # 
sex partners, frequency vaginal 
sex in past wk, anal sex in past 
3M, other STIs, bacterial 
vaginosis, candida, abnormal 
vaginal discharge on exam, 
abnormal cervical discharge on 
exam, incident HIV infection 
 
Final model (empirical selection): 
site, age, husband/partner earns 
income, frequency of vaginal sex 
past wk, T. vaginalis 
Not specified OCP All 
sites aOR: 
NR (ns) 
All sites, 
DMPA: 
aOR: NR 
(ns) 
 
All sites, 
Norplant 
aOR: NR 
(ns) 
 
Notes: PY: person-years at risk. * Statistically significant at p<0.05.  
a OCP type was unspecified unless COC (combined oral contraception) or POP (progestin-only pill) is noted.  
b Multiple incident cases per woman were allowed; included positive serology results from baseline, incident cases defined as a positive test following a negative test. 
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Table 7. Prospective associations between hormonal contraceptive use and T. vaginalis (TV) (N=9).  
Study N, study sample Length of 
follow-up; 
frequency 
STI 
assessment 
STI diagnostic 
test 
Covariates Reference 
group 
OCPa Injectable Implant or 
combined 
HC 
Balkus, 2014 
[34] 
2920, HIV-
negative women 
ages 18+ with no-
drug use in past 
12M in Blantyre, 
Lilongwe Malawi; 
Durban, Hlabisa, 
South Africa; 
Philadelphia USA; 
Lusaka Zambia; 
Harare, 
Chitungwiza, 
Zimbabwe, 
Detection at 
N=400 of 16,259 
visitsd 
12 to 30 M; 
0M, 12M, 
30M (or 
study exit) 
Vaginal wet 
mount via saline 
microscopy 
Age, marital status, 
unprotected sex in the last 
week, T. vaginalis at 
baseline, intermediate 
Nugent score, BV at prior 
visit 
 
 
Non-pregnant 
non-hormonal 
user 
OCP aHR: 0.64 
(0.47, 0.89)* 
Injectable 
(type not 
specified) 
aHR: 0.60 
(0.47, 0.78)* 
Implant (type 
not specified) 
aHR: 0.57 
(0.20, 1.60) 
 
 
Baeten, 
2001 [21] 
948, HIV-1 
negative sex 
workers in 
Mombasa, Kenya 
ages 16-48; 
N=435 incident 
cases (26.4/100 
PY) 
Range 15 to 
2366 days 
(median: 
421 days); 
median time 
b/w visits: 
35 days 
Vaginal wet 
mount 
Age, years of education, 
years of prostitution, parity, 
number of sexual partners, 
place of work (ie, bar vs. 
nightclub), number of sexual 
contacts per week, and 
condom usage 
Non-hormonal 
user or tubal 
ligation 
OCP aHR: 0.90 
(0.70, 1.30) 
DMPA aHR: 
0.60 (0.40 
1.0)* 
NA 
Barbone 
[24] 
818, U.S. women 
ages 19 to 29 
attending a STI 
clinic in 
Birmingham 
Alabama; N=171 
incident casese 
 
 
6M; Monthly Vaginal wet 
mount 
Spermicide use, sexual 
activity, age, race 
Tubal ligation or 
IUD user 
OCP: aHR 0.56 
(0.39, 0.81)* 
NA NA 
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Study N, study sample Length of 
follow-up; 
frequency 
STI 
assessment 
STI diagnostic 
test 
Covariates Reference 
group 
OCPa Injectable Implant or 
combined 
HC 
Borgdorff, 
2015 [37] 
381, HIV-negative 
sex workers in 
Kigali, Rwanda 
ages 18 to 49, 
N=89 incident 
casesb 
24M; 0M, 
6M, 12M, 
24M 
 
 
Vaginal swab via 
culture kit 
(InPouch, BioMed 
Diagnostics) and 
Gram stain 
(presence of 
>20% clue cells 
and Nugent 
criteria). 
Considered 
positive if tested 
positive on either 
test. 
Age, education, years 
worked as sex worker, 
breast-feeding, consistent 
condom use, antibiotic use 
past 14 d, ever used 
antibiotics, time duration 
between assessments 
Non-pregnant 
non-hormonal 
user  
OCP aOR: 0.61 
(0.20, 1.84) 
Injectable 
(type not 
specifiedf) 
aOR: 0.44 
(0.17, 1.10) 
 
 
NA 
Brahmbhatt, 
2014 [46] 
2374, HIV+ (304) 
and HIV- (2070) 
women ages 15 
to 49 in rural 
Rakai, Ugandac; 
N=96/2374 cases; 
2.4/100 PY 
12M; 0M, 
12M 
Self-collected 
vaginal swab via 
culture kit 
(InPouch, TV, 
BioMed 
Diagnostics) 
10-year age group, marital 
status, education, # sex 
partners past 12M, SES 
(home building materials), 
Nugent score for BV, 
condom use, syphilis result, 
HIV status 
 
Final model (empirical and 
theory informed): age, 
marital status, education, 
SES, condom use and other 
STIs, interaction b/w HC use 
and HIV status 
 
 
 
 
 
 
 
No method 
(neither 
hormonal or 
condom)  
COC past 12M 
aIRR: 1.02 (0.40, 
2.59); 
Consistently 
used COC (at 
baseline and 
follow-up) aIRR: 
1.07 (0.25, 4.56) 
DMPA past 
12M aIRR:  
0.54 (0.30, 
0.98)*; 
Consistently 
used DMPA 
only (at 
baseline and 
follow-up) 
aIRR: 0.59 
(0.28, 1.26) 
Norplant past 
12M aIRR: 
3.01 (1.07, 
8.49)*; 
Consistently 
used 
Norplant only 
(at baseline 
and follow-
up) aIRR: 3.13 
(1.08, 9.07)* 
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Study N, study sample Length of 
follow-up; 
frequency 
STI 
assessment 
STI diagnostic 
test 
Covariates Reference 
group 
OCPa Injectable Implant or 
combined 
HC 
Kapiga, 
2009 [47] 
958, HIV negative 
women ages 16 
to 62 in Lusaka, 
Zambia (ZA), 
Moshi Tanzania 
(TZ) and 
Durban/Hlabisa, 
South Africa (SA), 
Incidence rate: 
31.9/100 PY (all 
sites) 
 
12M; every 
3M 
 
 
Vaginal swab via 
Gram stain using 
Nugent criteria 
 
Age, site, partner earns 
income, # sex partners, 
frequency vaginal sex in past 
1W, anal sex in past 3M, 
other STIs, bacterial 
vaginosis, candida, 
abnormal vaginal discharge 
on exam, abnormal cervical 
discharge on exam, incident 
HIV infection 
 
Final model (empirical 
selection): site and incident 
HIV infection included in SA 
model and only age in TZ/ZA 
model 
Not specified OCP All sites 
aOR: 0.6 (0.3, 
1.0) 
All sites DMPA 
aOR: 0.7 (0.5, 
1.0) 
 
All sites 
Norplant 
aOR: NR (ns) 
 
Pettifor, 
2009 [48] 
567, HIV-negative 
women ages 18 
to 40 recruited 
from family 
planning clinics in 
Orange Farm, 
South Africa; 
N=47 incident 
infectionsb, 
incident rate: 10.2 
per 100 PY 
1Y; 0M, 2M, 
6M, 8M and 
12M (NET-
EN users) or 
0M, 3M, 6M, 
9M and 
12M (DMPA 
users and 
controls) 
 
  
Vaginal swabs via 
culture in 
Diamond’s media  
Age, relationship status, 
education, frequency of sex 
past 3M, # partners in past 
3M, condom use in past 3M, 
vagina douching past 3M, 
age of first sex  
 
Final model (empirical and 
theoretical selection): Age, 
education, condom 
consistency in past 3M 
Non-pregnant 
non-hormonal 
user 
NA DMPA aIRR: 
0.35 (0.12, 
1.01); NET-EN 
aIRR: 0.63 
(0.30, 1.29) 
NA 
Pintye, 2017 
[49] 
1271, HIV-
negative women 
enrolled during 
pregnancy and 
followed until 9M 
postpartum in 
western Kenya, 
median age 22 
(IQR: 19-27), 
~14M; 20, 
24, 32 and 
36 weeks 
gestation 
and post 
partum (2, 6, 
10 and 14 
weeks; 6 and 
9 months) 
Self-collected 
vaginal swabs 
treated with 
metronidazole, 
detection via wet 
mount 
microscopy 
Final model (empirical 
selection): employment, 
male partner circumcision 
status, pregnancy status and 
other non-TV curable STIs 
(CT, NG, T. pallidum, BV or 
candidas) detected at 
enrolment. 
Non-hormonal 
user  
OCP aHR: NR 
(ns) 
 
Injectable 
(type not 
specified) 
aHR: NR (ns) 
 
Implant (type 
not specified) 
aHR: NR (ns) 
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Study N, study sample Length of 
follow-up; 
frequency 
STI 
assessment 
STI diagnostic 
test 
Covariates Reference 
group 
OCPa Injectable Implant or 
combined 
HC 
N=112 incident 
infectionsb; 10.4 
per 100 PY 
Romer, 
2013 [50] 
342, adolescent 
girls ages 14-17 
attending clinics 
in inner-city areas 
of Indianapolis, 
USA; N=80 
incident casesb 
Originally 
27M, 
extended to 
5Y for some 
participants; 
every 3M 
 
Detection of T 
vaginalis DNA 
was performed 
using a 
modification of 
the Amplicor 
CT/NG PCR assay 
that included 
primers and 
probes specific  
for T vaginalis. 
 
Age, positive STI test at start 
of period, # of partners in 
past 3M, # of lifetime 
partners, # of sexual events 
in last 3M (diary period), # 
of unprotected sexual 
events in last 3M (diary 
period) 
Non-hormonal 
user 
NA DMPA use in 
current 3M 
period aOR: 
OR: 0.66 
(0.32, 1.36); 
DMPA use in 
prior 3M aOR: 
1.04 (0.52, 
2.08) 
NA 
Notes: PY: person-years at risk. * Statistically significant at p<0.05.  
a OCP type was unspecified unless COC (combined oral contraception) ) or POP (progestin-only pill) is noted.  
b Multiple incident cases per woman were allowed, i.e., incident cases defined as a positive test following a negative test. 
c All women tested negative for T. vaginalis at baseline. Incident cases were number of T. vaginalis positive women at follow-up (only 1 follow-up). 
d Women censored after first T. vaginalis incident, or if became pregnant, acquired HIV or tested positive for CT or NG. N=211 women who tested positive for T. vaginalis at 
baseline were included and prescribed treatment; N=39 [18%] of these women were also infected at the subsequent visit.  
e Women censored after first T. vaginalis incident. 
f Injectable type not reported but authors note most commonly DMPA in setting with occasional norethisterone enanthate use. 
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Figure 1. PRISMA Flow Chart 
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Figure 2. Use of hormonal contraception and human papillomavirus (HPV) infection. 
 
Notes: Findings are presented from studies considered to be high and moderate quality. 
NR (ns): estimate not reported due to non-significance.  Estimated risk is log transformed adjusted odds ratio, adjusted hazard 
ratio or adjusted rate ratio; OCP: oral contraceptive pill; COC: combined oral contraceptive pill; DMPA: Depot 
Medroxyprogesterone Acetate. Studies which report multiple outcomes are distinguished by subgroup. 
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Figure 3. Use of hormonal contraception and C. trachomatis infection.  
 
 
Notes: Findings are presented from studies considered to be high and moderate quality. 
Estimated risk is log transformed adjusted odds ratio, adjusted hazard ratio or adjusted rate ratio; OCP: oral contraceptive pill; 
COC: combined oral contraceptive pill; DMPA: Depot Medroxyprogesterone Acetate. Studies which report multiple outcomes 
are distinguished by subgroup. 
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Figure 4. Use of hormonal contraception and N. gonorrhoeae infection. 
 
Notes: Findings are presented from studies considered to be high and moderate quality. 
Estimated risk is log transformed adjusted odds ratio, adjusted hazard ratio or adjusted rate ratio; OCP: oral contraceptive pill; 
COC: combined oral contraceptive pill; DMPA: Depot Medroxyprogesterone Acetate. Studies which report multiple outcomes 
are distinguished by subgroup.
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Figure 5. Use of hormonal contraception and T. vaginalis infection. 
  
Notes: Findings are presented from studies considered to be high and moderate quality. 
NR (ns): estimate not reported due to non-significance. Estimated risk is log transformed adjusted odds ratio, adjusted hazard 
ratio or adjusted rate ratio; OCP: oral contraceptive pill; COC: combined oral contraceptive pill; DMPA: Depot 
Medroxyprogesterone Acetate. Studies which report multiple outcomes are distinguished by subgroup.
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Supplemental Digital Content Figure 1 
Pubmed search string: 
  
((((((hormonal AND contracepti*) OR (“hormonal methods”)) OR ((progestin* OR progestins[MeSH] OR 
Progesterone[MeSH]) AND contracept*) OR (oral contracept*) OR OC OR POP OR ((((depo OR depot) AND 
medroxyprogesterone) OR depo medroxyprogesterone OR depo OR depot OR dmpa OR “Sayana Press” OR “net 
en” OR “NET-EN” OR “norethisterone enanthate” OR norethisterone-enanthate OR Medroxyprogesterone 17-
Acetate[MeSH]) AND (contracept* OR inject*)) OR “Depo Provera” OR “Depo-Provera” OR (((levonorgestrel OR 
etonogestrel) AND implant) OR (uniplant OR jadelle OR implanon OR nexplanon OR norplant OR norplant2 OR sino-
implant)) OR (hormonal, transdermal[MeSH] OR (contracept* AND patch)) OR (contracept* AND pill) OR 
((levonorgestrel AND (intrauterine devices[MeSH] OR iud OR iucd OR ius OR “intrauterine system” OR “intra-
uterine system” OR “intrauterine device” OR “intra-uterine device”)) OR mirena) OR ((combin* AND inject* AND 
contracept*) OR ((“once a month” OR monthly) AND inject* AND contracept*) OR (cyclofem OR lunell OR 
mesigyna OR “cyclo provera” OR cycloprovera)) OR ((((contraceptive devices[MeSH] OR contraceptive 
agents[MeSH]) AND ring) OR nuvaring OR “nuva ring”)) OR ((((contraceptive devices[MeSH] OR contraceptive 
agents[MeSH]) AND patch) OR “ortho evra” OR ortho evra)) AND (“Sexually Transmitted Infection”[MeSH] OR “STI” 
OR (“sexually transmitted infect*”) OR “STD” OR “Gonorrhea”[MeSH] OR “ gonorrhoeae” OR “Chlamydia”[MeSH] 
OR “chlamydia trachomatis” OR “Chancre”[MeSH] OR chancroid OR “haemophilus ducreyi” OR 
“Trichomonas”[MeSH] OR “Trichomoniasis”[MeSH] OR “trichomonas vaginalis” OR “TV” OR “Treponema 
pallidum”[MeSH] OR herpes OR herpesvirus OR “herpes simplex” OR “herpes virus” OR HSV OR “Human 
papillomavirus”[MeSH] OR “HPV” OR “Syphilis”[MeSH] OR “genital warts” OR “condylomata”)) OR (injectable 
contracepti* STI) OR (oral contracepti* STI) OR (CT OR GC OR NG AND “sexually transmitted infection”) OR (CT OR 
GC OR NG AND STI))) AND (“2009/01/01”[EDAT] : “2017/06/15”[EDAT])) 
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EMBASE search string  
  
hormonal AND contracepti* OR ‘hormonal methods’ OR (progestin* OR ‘progestins’ OR ‘progesterone’ AND 
contracept*) OR (‘oral’ AND contracept*) OR ‘OC’ OR ‘POP’ OR ((depo OR depot) AND ‘medroxyprogesterone’) OR 
depomedroxyprogesterone OR depo OR depot OR dmpa OR ‘sayana press’ OR ‘net en’ OR ‘net-en’ OR 
‘norethisterone enanthate’ OR ((‘medroxyprogesterone’ AND ’17-acetate’) AND (contracept* OR inject*)) OR 
((‘levonorgestrel’ OR ‘etonogestrel’) AND ‘implant’) OR ‘uniplant’ OR ‘jadelle’ OR ‘implanon’ OR ‘nexplanon’ OR 
‘norplant’ OR norplant2 OR ‘sino implant’ OR (hormonal AND transdermal) OR (contracept* AND patch) OR 
(‘levonorgestrel’ AND ‘intrauterine’ AND ‘devices’) OR ‘iud’ OR ‘iucd’ OR ius OR ‘intrauterine system’ OR ‘intra-
uterine system’ OR ‘intrauterine device’ OR ‘intra-uterine device’ OR ‘mirena’ OR (combin* AND inject* AND 
contracept*) OR ((‘once a month’ OR monthly) AND inject* AND contracept*) OR ‘cyclofem’ OR ‘lunelle’ OR 
‘mesigyna’ OR ‘cyclo provera’ OR ‘cycloprovera’ OR ((‘contraceptive’ AND ‘devices’) OR (‘contraceptive’ AND 
agents) AND ring) OR ‘nuvaring’ OR ‘nuva ring’ OR ((‘contraceptive’ AND ‘devices’) OR (‘contraceptive’ AND agents) 
AND patch) OR ‘ortho evra’ OR orthoevra AND (‘sexually transmitted infection’ OR STI OR ‘sexually transmitted 
infections’ OR STD ‘sexually transmitted disease’ OR ‘sexually transmitted diseases’ OR gonorrhea OR ‘neisseria 
gonorrhoeae’ OR chlamydia OR ‘chlamydia trachomatis’ OR chancre OR chancroid OR ‘haemophilus ducreyi’ OR 
trichomonas OR trichomoniasis OR ‘trichomonas vaginalis’ OR TV OR ‘treponema pallidum’ OR herpes OR 
herpesvirus OR ‘herpes simplex’ OR ‘herpes virus’ OR hsv OR ‘human papillomavirus’ OR hpv OR syphilis OR 
‘genital warts’ OR condylomata) OR (injectable contracepti* STI) OR (oral contracepti* STI) OR (CT OR GC OR NG 
AND ‘sexually transmitted infection’) OR (CT OR GC OR NG AND STI) AND [humans]/lim AND [1-1-2009]/sd NOT 
[15-6-2017]/sd AND ([article]/lim OR [article in press]/lim)
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Supplemental Digital Content Table 2: Quality assessment of prospective or retrospective cohort studies. 
Citation Study design Reference 
group drawn 
from same 
community as 
HC users (2) 
Ascertainment 
of HC use (2) 
Demonstration 
STI not present 
prior to 
incident/recurrent 
infection (1) 
Comparability 
of HC users 
and reference 
group cohorts 
demonstrated 
or adjusted 
for (2) 
Ascertainment 
of STI based 
on biomarker 
and blind to 
HC status (2) 
Adequate 
follow-up of 
cohort (<20% 
lost or 
unlikely to 
introduce 
bias) (1) 
Total score 
 
Quality rating: 
High (8-10) 
Medium (5-7) 
Low (<5) 
Balkus 2014 [34] Secondary 
RCT 
2 2 1 2 1 1 9 (High) 
Baeten 2001 [21] PC 2 2 0 2 1 0 7 (Medium) 
Barbone 1990 [24] Secondary 
RCT 
2 1 1 1 1 0 6 (Medium) 
Borgdorff 2015 [37] PC 2 2 1 2 1 1 9 (High) 
Brahmbhatt 2014 
[46] 
PC 1 1 1 2 1 0 6 (Medium) 
Chohan 2009 [53] PC 1 1 1 2 1 1 7 (Medium) 
Gosvig 2013 [38] PC 2 2 1 2 2 0 9 (High) 
Grabowski 2015 [35] Secondary 
RCT 
2 1 1 2 1 0 7 (Medium) 
Kapiga 2009 [47] PC 0 1 1 1 1 0 4 (Low) 
Lavreys 2004 [22] PC 1 2 0 1 1 0 5 (Medium) 
Lekovich 2015 [39] RC 2 1 1 1 1 0 6 (Medium) 
Louv 1989 [23] Secondary 
RCT 
1 2 1 1 1 0  6 (Medium) 
Louvanto 2011 [40] PC 0 1 1 1 1 0 4 (Low) 
Low 2014 [55] PC 1 2 1 1 0 0 5 (Medium) 
Marks 2011 [41] PC 2 2 1 2 1 0 8 (High) 
Masese 2013 [51] PC 1 2 1 2 1 0 7 (Medium) 
Morrison 2004 [25] PC 2 1 1 2 0 1 7 (Medium) 
Moscicki 2001 [26] PC 1 2 1 1 1 0 6 (Medium) 
Nielsen 2009 [42] PC 1 1 1 2 2 0 7 (Medium) 
Pettifor 2009 [48] PC 2 2 1 2 1 1 9 (High) 
Phelan 2009 [43] PC 1 2 1 1 1 0 6 (Medium) 
Pintye 2017 [49] PC 2 2 1 2 1 0 8 (High) 
Romer 2013 [50] PC 1 2 1 2 1 1 8 (High) 
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Russell 2016 [52] PC 1 2 1 2 1 1 8 (High) 
Sellors 2003 [28] PC 1 1 1 1 1 0 5 (Medium) 
Shew 2015 [44] PC 1 2 1 2 1 0 7 (Medium) 
Socias 2017 [54] PC 0 2 1 2 1 0 6 (Medium) 
Winer 2003 [27] PC 0 2 1 2 1 0 6 (Medium) 
Winer 2016 [45] PC 0 0 0 2 1 0 3 (Low) 
Notation: PC: prospective cohort, RC: retrospective cohort, Secondary RCT: secondary analysis of RCT. NR: not reported. NA: This criterion was not applicable: 
studies estimated recurrent infection. 
Rating criteria: Non-users drawn from same community as HC users: a) respondents drawn from the same community as HC users (i.e., does not include 
pregnant women) (1 point) and b) comparison group does not include users of another HC method (unless intentional head-to-head comparison (1 point). 
Ascertainment of HC use: a) separate estimates for different types of HCs (1 point), b) HC use assessed more than once and at intervals <6 months (1 point). 
Demonstration STI not present at start of study: test for pathogen used to confirm respondents were STI negative at study start (1 point). Comparability of 
cohorts demonstrated:  a) adjusted analyses performed (1 point); b) authors adjust for condom use or demonstrates negligible difference (1 point); 
Ascertainment of STI: a) independent blind assessment of STI performed (1 point); b) separate estimates for different types of STIs provided using test for 
pathogen (1 point); Adequacy of follow-up of cohorts: a) subjects lost to follow-up unlikely to introduce bias (either high retention >80% or description of those 
lost is provided and comparable to those who remain in the study) (1 point).   
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Supplemental Digital Content Table 3: Quality assessment of case-control studies. 
Citation STI case 
definition 
accurate (1) 
Representativeness 
of cases (1) 
Control 
selection (1) 
and 
definition (1)  
Comparability 
of cases and 
controls in 
design or 
analysis (2) 
Ascertainment 
of HC (3) 
Same 
ascertainment 
method for 
cases and 
controls (1) 
Comparable 
non-
response 
rate for cases 
and controls 
(1) 
Total score 
 
Quality 
rating: 
High (8-10) 
Medium (5-7) 
Low (<5) 
Harris 2009 [36] 1 0 2 1 2 1 0 7 (Medium) 
Rating criteria: STI definition accurate: separate estimates for different types of STIs provided using test for pathogen (1 point); Representation of cases: 
consecutive or obviously representative series of cases; Control selection & definition: a) controls are sampled independent of HC use and from same source 
population of cases (1 point); b) if cases are first occurrence of outcome, then controls stated to have no history of outcome. If cases have new (not necessarily 
first) occurrence of outcome, then controls with previous occurrences of outcome of interest are not excluded (1 point); Comparability of cases and controls in 
design or analysis: a) adjusted analyses are performed (1 point); b) study controls for condom use or negligible differences reported in adjusted in unadjusted 
models (1 point);  Ascertainment of HC:  a) separated estimates for different types of HCs (1 point); b) HC use is assessed more than once at intervals <6 
months (1 point); c) HC ascertainment is through structured interview blind to case-control status (1 point); Same ascertainment method for cases and 
controls: yes or no (1 point); Comparable non-response rate: equivalent rate demonstrated for both groups (1 point). 
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Short summary: A systematic review of the association between hormonal contraception and 24 
incident STIs found that DMPA and oral contraceptive pills decrease risk of trichomoniasis, and 25 
DMPA may increase risk of HSV-2.  26 
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Abstract  31 
Background: Evidence suggests that some forms of hormonal contraception (HC) increase 32 
women’s risk of non-HIV sexually transmitted infections (STIs), yet evidence has not been 33 
reviewed since 2008. We conducted an updated systematic review to incorporate studies 34 
published between January 2009 and June 2017 to examine the relationship between HCs and 35 
incident and/or recurrent STIs. 36 
Methods: We searched PubMed and EMBASE to identify prospective studies comparing risk of 37 
Chlamydia trachomatis, Neisseria gonorrhoeae, human papillomavirus (HPV), herpes simplex 38 
virus type 2 (HSV-2), Treponema pallidum, or Trichomonas vaginalis, between women using HC 39 
vs. non-hormonal methods or no methods. We summarize results by type of STI and HC and 40 
study quality using an adapted Newcastle-Ottawa Quality Assessment Scale. 41 
Results: Thirty articles met the inclusion criteria. Depo-medroxyprogesterone acetate (DMPA) 42 
reduces the risk of trichomoniasis (consistent evidence) and may increase the risk of HSV-2 43 
(strong effect, few studies); inconclusive evidence exists for HPV, chlamydia, gonorrhea and 44 
syphilis. Data on oral contraceptive pills (OCPs; generally not differentiated whether combined 45 
or progestin-only pills) suggest use is associated with a reduced risk of trichomoniasis with 46 
inconclusive findings for HSV-2, HPV, chlamydia, gonorrhea, and syphilis. Very few studies 47 
included norethisterone enanthate (Net-En) injectable, implants or the levonorgestrel IUD. 48 
Conclusions: DMPA and OCPs reduce the risk of trichomoniasis and DMPA may increase the risk 49 
of HSV-2. However, the potential for confounding cannot be ruled out. Future studies should 50 
specify the type of injectable or OCP used to increase understanding of biological pathways; 51 
more research is needed on implants and hormonal IUDs.  52 
 4 
Introduction 53 
While access to hormonal contraception (HC) reduces unwanted pregnancy and maternal 54 
morbidity and mortality, a body of evidence from recent systematic reviews, meta-analyses and 55 
in vivo and in vitro studies suggest that the progestin injectable depo-medroxyprogesterone 56 
acetate (DMPA) increases risk of HIV acquisition [1–5]. Comparatively less emphasis, however, 57 
has focused on the potential association of DMPA and other HC and other sexually transmitted 58 
infections (STIs).  59 
 60 
Several biological mechanisms by which HC use may facilitate STI acquisition have been 61 
proposed including through changes in the protective cervicovaginal epithelial barrier 62 
from hypo-estrogenism induced by progestin-only methods [6,7]. A second mechanism is 63 
through weakening of immune defense [8]. For example, DMPA is known to bind to 64 
glucocorticoid receptors, which generally results in immune modulation [5,9]. Third, hypo-65 
estrogenism induced by progestin-only methods could lead to changes in the vaginal microbiota 66 
composition, leading to vaginal dysbiosis and inflammation [10], which in turn could lead to 67 
epithelial breaches and mucus degradation [11,12]. At a behavioral level, HC use may result in 68 
decreased condom use, thereby increasing risk of STI exposure [13,14].  69 
 70 
Two prior systematic reviews have examined the association between HCs and STI acquisition; 71 
evidence has not been synthesized since 2008 [15,16]. Both reviews found that OCP and DMPA 72 
users had a possible increased risk of chlamydia but concluded there was inconclusive evidence 73 
for gonorrhea, herpes simplex virus type 2 (HSV-2), trichomoniasis, syphilis and human 74 
 5 
papillomavirus (HPV). Given the magnitude of women using HC globally and the negative health 75 
repercussions of many STIs, we conducted an updated systematic review to incorporate 76 
literature from longitudinal studies published between 2009 and 2017 on the association 77 
between the HC use and non-HIV STI acquisition; systematic reviews on HIV acquisition have 78 
been updated regularly [1–4].   79 
 80 
Materials and Methods 81 
The protocol was registered a priori with PROSPERO [Record 42017069357] and follows PRISMA 82 
guidelines (Supplemental Table 1). Articles were identified using key term searches of two 83 
electronic databases: PubMed and EMBASE (Supplemental Figure 1).  84 
 85 
Inclusion/exclusion criteria 86 
Included articles were peer reviewed, published in English, Spanish or French between 01 87 
January 2009 and 30 June 2017 and measured incident/recurrent cases of cervicovaginal HPV, 88 
HSV-2, chlamydia, gonorrhea, syphilis, and/or trichomoniasis, with laboratory diagnostic tests, 89 
among HC users compared with non-users or users of non-hormonal methods. All HC methods 90 
were included except for emergency contraception, since it is typically used in combination 91 
with other contraceptive methods [17].  We also reviewed articles identified from two earlier 92 
systematic reviews [15,16]; articles from these reviews which met our criteria are also included. 93 
 94 
We excluded cross-sectional studies, review articles, studies which relied on clinical exam or 95 
self-reported STIs, and studies which did . not control for potential confounding variables. WWe 96 
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also excluded studies of HCs and HIV and bacterial vaginosis (BV), as both have been recently 97 
reviewed [18,19]. Two independent reviewers [KJM & HEJ or ELG] screened each abstract or 98 
article using Covidence software; a third reviewer who had not previously reviewed the study 99 
[HEJ or ELG] resolved discrepancies. 100 
 101 
Data Extraction 102 
One reviewer [KJM] extracted data, with independent review for accuracy [HEJ or ELG]. 103 
Extracted information included: participant characteristics, geographic location, sample size, 104 
sampling method, contraceptive method, duration of use, comparison group, STI, whether 105 
infection was incident or recurrent, STI diagnostic test, confounders in adjusted estimates, type 106 
of statistical analysis, treatment of missing data, length of time between exposure and outcome 107 
assessment, and the effect estimate, variance and significance level.  108 
 109 
Study quality 110 
Risk of bias was assessed using the Newcastle-Ottawa Quality Assessment Scale [20], adapted 111 
to reflect challenges identified previously for assessment of the relationship between HC use 112 
and STIs/HIV [3,15] (Supplemental Tables 2 and 3). Two reviewers [KJM & HEJ or ELG] 113 
independently rated study quality; discrepancies were resolved by discussion among all three 114 
reviewers.  115 
 116 
Data synthesis 117 
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Our primary outcome is incident STI. We examined findings by HC method used (e.g., OCP, 118 
DMPA, levonorgestrel IUD, Net-En, Norplant) and type of STI. Forest plots were constructed 119 
using the forestplot package in R Studio (Version 1.1.383, Vienna, Austria).  120 
 121 
Results 122 
Our key term search resulted in 1,477 unique articles, 1,284 articles were excluded during 123 
abstract screening; 24 required full-text review of which two were excluded (Figure 1). An 124 
additional 13 prospective studies identified in the previous two systematic reviews were 125 
considered for inclusion. Of these eight met our study inclusion criteria and are included [21–126 
28], five did not meet our criteria [29–33]. The 30 reviewed studies were all prospective and 127 
observational in design, most were longitudinal cohort studies (N=25), four were secondary 128 
analysis of a randomized control trial [23,24,34,35] and one used a nested case-control design 129 
[36].  130 
 131 
The majority of articles assessed the incidence or recurrence of HPV (n=13) [26,27,43–132 
45,28,36–42], followed by trichomoniasis (n=9) [21,24,34,37,46–50], chlamydia (n=9) [21–133 
23,37,47,48,50–52], gonorrhea (n=7) [21–23,37,47,48,50], HSV-2 (n=4) [35,37,53,54], and 134 
syphilis (n=3) [24,37,47] (not mutually exclusive). Two studies combined incident chlamydia 135 
and/or gonorrhea [25,55]. Twelve studies included women ages 18-50 years [22–136 
24,27,36,37,41,42,48,51,53,55], ten studies included adolescents (<age 18 years) 137 
[21,25,26,28,35,44,46,47,50,52], three included women older than age 49 years [34,45,47] and 138 
five did not report age range, but the majority of participants were of reproductive age [38–139 
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40,43,49]. One-third of studies enrolled populations considered at increased STI risk: women 140 
reporting transactional sex (n=6) [21,22,37,51,53,54], injection drug use (n=1) [43], lower 141 
genital tract infection/partner with diagnosed STI (n=1) [52], or living with HIV (n=2) [22,55]. 142 
Three additional studies included women living with and without HIV [43,46,54]. 143 
 144 
Half of the studies (15 of 30) compared HC users to non-hormonal method users (e.g., condom), 145 
twelve studies compared two or more types of HCs [23,24,26–28,36,39,40,43,44,52,54], three 146 
compared HC use to women not using any method and/or women who were sterilized 147 
[21,22,46].  148 
 149 
Study quality assessment and risk of bias 150 
Most studies were considered high (n=8) or medium (n=19) quality (Supplemental Tables 2 and 151 
3). Low quality studies (n=3) are presented in the data tables, but not included in forest plots or 152 
discussed [40,45,47].  153 
 154 
Despite medium/high quality, a number of methodological challenges remained. Nearly all 155 
studies relied on self-reported HC exposure, despite known limitations [9]. Most studies (20 of 156 
25) did not distinguish between combined or progestin only OCPs, and some did not distinguish 157 
between DMPA and Net-En injectable (3 of 19). The reference group of non-users of a given HC 158 
was not defined consistently and sometimes included users of other forms of contraception.  159 
Most studies employed empirically driven rather than theoretical adjustment for confounding. 160 
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Non-significant estimates were not always presented, prohibiting information on the direction 161 
of association. For some studies, incidence rates were low suggesting limited power.  162 
 163 
HPV 164 
Eleven studies evaluated the risk of HC on incident HPV infection and provide inconclusive 165 
evidence of association (Table 1, Figure 2). All diagnostic tests were DNA-based and five 166 
assessed one or more high-risk HPV (HR-HPV) types, one assessed one or more low-risk HPV 167 
(LR-HPV), while eight considered any HPV type; two disaggregated results more than one way. 168 
Four studies assessed the influence of injectables; two found that incidence of HR (one study) 169 
or any HPV (one study) was lower but not significantly lower compared to non-HC users [37,41]. 170 
A third study found recent DMPA users had increased incident HR-HPV (used in past six months 171 
aOR: 1.6; 95%CI: 0.7, 3.7) and long-term users (≥1 year of use aOR: 4.7; 95%CI: 1.4, 15.8) 172 
relative to non-users of DMPA [36]. Findings were in the same direction but not statistically 173 
significant among short term and former users. The fourth study found non-significant results in 174 
mixed directions, depending on HPV type [44]: DMPA use was associated with lower incidence 175 
of HR and increased risk of LR-HPV. 176 
 177 
Ten studies evaluated OCP use. Three reported OCP use to be associated with increased HPV 178 
risk [27,42,44], two found non-significant increased risk, [37,41] one found significant 179 
decreased risk [26], two reported non-significant decreased risk [28,36], one found no effect 180 
[38] and one did not report the effect estimate for non-significant findings [43]. Only two 181 
studies specified combined OCP use (COC), both documented a non-significant association 182 
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[36,41]. Of the studies which documented evidence of increased risk, one was among OCP users 183 
vs. non-OCP users in the last three months among LR-HPV (aHR: 2.73; 95%CI: 1.52, 4.90) and 184 
all-HPV types (aHR: 2.0; 95%CI: 1.28, 3.15), but not HR-HPV types [44]. Another study which 185 
also assessed OCP users vs. non-OCP users on all-HPV types found a lower magnitude of 186 
increased risk (aHR: 1.40, 95%CI: 1.01, 1.80) [27]. The final significant finding of increased risk 187 
was documented in the longest exposure group only (7+ years) (aOR: 1.66; 95%CI: 1.17, 2.35), 188 
with attenuated evidence of marginal risk in lower exposure groups (5-6 year and 3-4 year 189 
groups) and null effects among users <2 years relative to nonusers of HC [42]. The one study 190 
that found significant decreased risk was among OCP using U.S. women attending a family 191 
planning clinic relative to non-current OCP users (aHR: 0.49, 0.28, 0.86) [26]. Overall, 192 
inconsistent exposure groups (current versus ever user), reference group (non-current versus 193 
never user) and differences in HPV-subtype may contribute to disparate findings. 194 
 195 
Only one study assessed the risk of hormonal IUD use on incident HPV infection. This 196 
retrospective record review compared levonorgestrel IUD users to copper IUD users and 197 
documented a four-fold higher risk of HR-HPV among the former [39]. This effect was 198 
marginally significant and based on few incident cases. 199 
 200 
HSV-2  201 
Studies examining HSV-2 acquisition provide some evidence that injectable use increases risk 202 
[35,37,54] and inconclusive evidence regarding OCPs [35,37,53,54] (Table 2).  203 
 204 
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Three studies examined the risk of injectable use on HSV-2 incidence. Two studies reported 205 
evidence of a significantly increased risk following injectable use (one specifies DMPA, the other 206 
is unspecified) [35,54]. The remaining study reports evidence of non-significant increased risk 207 
(injectable type unspecified) [37]. The two studies that did not record the injectable type 208 
reported that DMPA was most common. Of the two studies that documented a significant 209 
effect, one study among HIV-negative women in Uganda reported increased risk (aOR: 2.26, 210 
95%CI: 1.09, 4.69) among consistent DMPA users, but not those who discontinued use, relative 211 
to non-HC users [35]. The other study found DMPA use relative to non-DMPA use was strongly 212 
associated with HSV-2 acquisition among women both living with and without HIV (aHR: 4.43, 213 
95%CI: 1.90, 10.35), and when restricted to women living without HIV (aHR: 3.97, 95%CI: 1.64, 214 
9.60) [54]. The third study documented non-significant evidence of increased risk among HIV-215 
negative women who engaged in sex work and used DMPA (aOR: 6.34, 95%CI: 0.25, 158.5) 216 
compared to non-HC users, [37] based on only five incident cases among DMPA users. 217 
 218 
Three studies examined HSV-2 acquisition among OCP users: two documented a non-significant 219 
reduced risk of HSV-2 among OCP users relative to non-HC users [35,53]. The remaining study 220 
was in the harmful direction but was based on only two incident cases among OCP users [37].  221 
 222 
Chlamydia  223 
Seven studies provide inconclusive evidence of increased risk of chlamydia among injectable 224 
users [21,22,37,48,50–52] and three provide inconclusive evidence regarding OCP use 225 
[23,37,51] (Table 3, Figure 3).  226 
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 227 
Of the seven studies among injectable users, three documented a significant increased risk of 228 
acquisition among DMPA users [21,22,51]. The magnitude of increased risk ranged between 1.6 229 
(95%CI: 1.1, 2.4) fold among DMPA users relative to women who were sterilized or using no 230 
contraception [21] to 3.1 (95%CI: 1.0, 9.4) among women living with HIV-1 who used DMPA 231 
compared to those who were sterilized or used IUD [22]. The latter effect was marginally 232 
significant (p=0.05). Four studies found a non-significant increased risk of acquisition among 233 
DMPA users relative to non-HC users [37,48,50]; the direction of effect varies by the reporting 234 
period in one study but remains non-significant [50]. An additional study documented a hazard 235 
ratio close to one among women who reported DMPA at any fourth month visit relative to non-236 
DMPA users [52]. Only one study compared norethisterone enanthate (Net-En) users to non-HC 237 
users, and found a non-significant reduced risk of infection [48].  238 
 239 
Six studies examined the incidence of chlamydia among OCP users [21–23,37,51,52], only one 240 
study specified combined or progestin-only pill use [23]. Three studies documented significant 241 
evidence of increased risk [21,23,37]. One study among HIV-negative women engaging in sex 242 
work in Rwanda compared OCP users to non-HC users (aOR: 6.13, 95%CI: 1.5, 23.8) [37]. Results 243 
from this study are based on few incident cases. The two other studies documented significant 244 
increased risk of similar magnitude. One study compared OCP users to women who were 245 
sterilized or using no contraceptive (aHR: 1.80, 95%CI: 1.10, 2.90) [21], the other compared OCP 246 
users to women who were sterilized or using IUD (aHR: 1.73, 95%CI: 1.08, 2.77) [23].  Three 247 
studies reported null findings. One study did not report the effect coefficient [52], and the 248 
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other found non-significant reduced risk (aHR: 0.2, 95%CI: 0.0, 1.7), among OCP users relative 249 
to non-HC users [51]. 250 
  251 
Gonorrhea  252 
We found no significant prospective evidence that injectable use (five studies) [21,22,37,48,50], 253 
was associated with risk of gonorrhea.  Only one of four studies of OCP use showed increased 254 
the risk of gonorrhea [21–23,37] (Table 4, Figure 4).  Of the three studies which compared 255 
injectable users to non-HC users, two studies found non-significant evidence of increased risk 256 
among DMPA users [48,50], one found non-significant evidence of reduced risk among Net-En 257 
users [48], and one study found non-significant evidence of reduced risk (injectable type 258 
unspecified) [37]. Two additional studies which examined DMPA use relative to women who 259 
were sterilized or used no contraception found an association close to the null [21,22]. One of 260 
these was among women who were living with HIV-1 [22]. Information from the one study 261 
which found increased risk of gonorrhea following OCP use found nearly double risk (aHR 1.7, 262 
95%CI: 1.05, 2.76) among COC users relative to women who used an IUD or were sterilized  263 
[23]. This was the only study to assess pill formulation and found that a higher ratio of 264 
progestin in COC had a nonsignificant, but positive correlation with the risk of gonorrhea 265 
acquisition. The other three studies evaluating OCP use found results in mixed directions and 266 
did not specify pill type. 267 
 268 
Combined STI  269 
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Two studies evaluated a combined group of women who tested positive for either C. 270 
trachomatis or N. gonorrhoeae due to small sample sizes (Table 5) [25,55]. A study among 271 
American STI patients found significant increased risk among DMPA users (aHR: 3.6, 95%CI: 1.6, 272 
8.5), and non-significant increased risk among COC users (aHR: 1.5, 95%CI: 0.6, 3.5) relative to 273 
non-HC users [25]. The second study was among HIV-1 positive women on antiretroviral 274 
therapy was unable to evaluate OCP use due to no incident infections among users. However, 275 
women who used DMPA had more than five times the incident risk of N. gonorrhoeae or C. 276 
trachomatis (combined) (aOR: 5.83, 95%CI: 0.90, 37.7), relative to non-HC users [55].   277 
 278 
Syphilis 279 
Two studies assessed HC use on syphilis incidence (Table 6), both which found non-significant 280 
results. One study found non-significant evidence of increased risk among Kenyan women who 281 
engaged in commercial sex work and used OCPs (aHR: 0.40, 95%CI: 0.10, 1.50) and DMPA (aHR: 282 
0.50, 95%CI: 0.20, 1.40), relative to women who used no contraception or were sterilized [21]. 283 
The other study found non-significant evidence of increased risk among HIV-negative sex 284 
workers in Rwanda who used any injectable relative to non-HC users (aOR: 1.43, 95% CI: 0.11, 285 
19.1) [37]. The finding, however, is based on only four incident cases.  286 
 287 
Trichomoniasis 288 
Studies of HC use on risk of trichomoniasis suggest injectables and OCPs are associated with 289 
reduced risk while findings are mixed regarding implant use (Table 7, Figure 5) 290 
[21,24,34,37,46,48–50]. 291 
 15 
 292 
All seven studies that measured incident trichomoniasis suggest that injectable use reduced 293 
incidence by a magnitude ranging from 0.35 (95%CI: 0.12, 1.01) to 0.70 (95%CI: 0.50, 1.0), 294 
though some results were not statistically significant. Three studies found significant reduced 295 
risk following injectable use (two specified DMPA and one was unspecified) [21,34,46] and two 296 
documented reduced risk that approached significance (one specified DMPA, one was 297 
unspecified but DMPA use was most common) [37,48]. Two of the studies which documented 298 
significant evidence of reduced risk compared HIV-1 negative injectable users (type unspecified) 299 
to non-HC users (aHR: 0.60, 95%CI: 0.47, 0.78), and DMPA users (aHR: 0.60, 95%CI: 0.4, 1.0, 300 
p=0.04) to women who were sterilized or did not use contraception [21,34]. The third study 301 
found women in Uganda who reported DMPA use in the past 12 months were at decreased risk 302 
compared to women who used neither HC nor condoms (aIRR: 0.54, 95%CI: 0.30, 0.98) [46]. 303 
Notably, the same study found non-significant findings of a similar magnitude among women 304 
who reported consistently using only DMPA at baseline and follow-up (aIRR: 0.59, 95%CI: 0.28, 305 
1.26). Only one study reported results for Net-En relative to non-HC use and found non-306 
significant reduced risk [48]. 307 
 308 
Six of seven studies that assessed OCP use and trichomoniasis documented reduced risk, 309 
although only two were significant. One significant finding was reported in a study among OCP 310 
users in five countries (Malawi, South Africa, the United States, Zambia and Zimbabwe) who 311 
were significantly less likely to acquire T. vaginalis relative to non-HC users (aHR: 0.64, 95%CI: 312 
0.47, 0.89) [34]. The other was among OCP using women attending a STI clinic in the U.S. 313 
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relative to those who used IUD or were sterilized (aHR: 0.56, 95%CI: 0.39, 0.81) [24]. Only one 314 
study specified COC use [46]. This study documented null findings among women in Uganda 315 
who reported COC use in the past twelve months (aIRR: 1.02, 95%CI: 0.40, 2.59), or consistently 316 
using COCs in the past 12 months (aIRR: 1.07, 95%CI: 0.25, 4.56) relative to no method (neither 317 
hormonal nor condom). 318 
 319 
One of three studies which assessed implant use on incident trichomoniasis found a three-fold 320 
increased risk of trichomoniasis (aIRR: 3.01, CI: 1.07, 8.49) among Norplant users relative to 321 
women who used no contraception method (hormonal or condoms) and slightly higher risk 322 
among consistent users of Norplant for 12 months (aIRR: 3.13, 95% CI: 1.08, 9.07) [46]. The two 323 
remaining studies found no relationship between implant use (type unspecified) and 324 
trichomoniasis [34,49].  325 
 326 
 327 
Discussion 328 
Among studies of sufficient quality, DMPA use is consistently associated with a reduced risk of 329 
T. vaginalis acquisition, with evidence of substantial (two times or higher) increased risk of HSV-330 
2 incidence from a smaller number of studies. The results for HPV, chlamydia, gonorrhea and 331 
syphilis were inconclusive. Net-En was only assessed in one study [48]. Data on OCP use suggest 332 
reduced incidence of trichomoniasis, with inconclusive findings for HPV, HSV-2, chlamydia, 333 
gonorrhea and syphilis. Implant use was less studied (n=3), and only one specified type 334 
(Norplant). This study documented increased risk of trichomoniasis, but did not assess other 335 
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STIs [46]. Only one study assessed the levonorgestrel IUD and found a higher risk of HR-HPV 336 
incidence compared to the copper IUD; however, findings were marginally significant [39]. 337 
 338 
Findings from our study differ somewhat from two previous systematic reviews, which found 339 
inconclusive results for DMPA and OCPs on incident trichomoniasis, and increased risk of 340 
incident chlamydia [15,16]. However, one previous review primarily synthesized cross-sectional 341 
research [16]. In the second review, half of the studies (2 of 4 for trichomoniasis; 3 of 6 for 342 
chlamydia) did not include statistical adjustment for confounding [15]. Those studies that 343 
reported adjusted T. vaginalis analyses also found decreased risk [21,24]. Prior prospective 344 
evidence of incident HPV from four studies [26–28,31] also suggest mixed results regarding the 345 
influence of OCPs and DMPA [26],Figure without clear trends by HPV type or exposure time.  346 
 347 
This review provides limited evidence that DMPA is associated with increased risk of HSV-2; we 348 
identified no prior review of HC use on incident HSV-2. Notably, our findings are based on a 349 
small number of studies. However, findings correspond with studies in mice which show 350 
heightened susceptibility to HSV-2 following prolonged (>2 weeks) treatment with DMPA 351 
[56,57]. These findings align with the one study that examined multiple exposure periods to 352 
DMPA and found a two-fold increased risk of HSV-2 in consistent DMPA users relative to non-353 
HC users but not among those who initiated, or discontinued use [35]. A recent study in mice 354 
demonstrated that both DMPA and levonorgestrel, another progestin, increase mucosal 355 
epithelial permeability by acting on epithelial cell junction proteins (DSG1α), enhancing access 356 
of inflammatory and infectious viral molecules to the genital tissue, a possible biological 357 
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mechanism [7].  Given substantial evidence that HSV-2 increases risk of HIV infection, [58] if the 358 
finding that DMPA increases the risk of HSV-2 is substantiated, this could be a mechanism for 359 
the association between DMPA use and HIV acquisition. 360 
 361 
Further prospective research is warranted in several areas. Very few studies have explored the 362 
prospective association between HC use and syphilis (n=3) or HSV-2 (n=4) incidence. Similarly, 363 
few prospective studies have explored the potential risk of Net-En (n=1), levonorgestrel IUD 364 
(n=1) or implants on STIs (n=3), while use of these methods is increasing [59]. No reviewed 365 
studies evaluated Sayana Press, the Nuva Ring, or patch. Current large-scale prospective studies 366 
of HIV risk among women should incorporate well measured contraceptive use and STI 367 
outcomes to help address these gaps. Further many of the studies of OCPs did not differentiate 368 
between combined or progestin-only OCPs and similarly some injectable studies did not 369 
differentiate between Net-En and DMPA.  Given that biological responses to HC differ by class 370 
of drug as well as drug formulations,[5] future research needs to distinguish between HC 371 
formulations when estimating risk of STI/HIV acquisition.   372 
 373 
This updated systematic review of prospective evidence published between 2009 and 2017 374 
suggests that DMPA and OCP use are associated with a reduced risk of incident trichomoniasis, 375 
with evidence of increased substantial risk of HSV-2 acquisition with DMPA use from a small 376 
number of studies. Our review findings are tempered by notable methodological limitations. 377 
Prospective evidence regarding the STI risk of hormonal contraceptive methods are extremely 378 
limited or non-existent, highlighting an urgent research need.   379 
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Table 1. Prospective associations between hormonal contraceptive use and Human Papillomavirus (HPV) (N=13). 
Study N, study sample Length of follow-
up; frequency STI 
assessment 
STI diagnostic test Covariates Reference 
Group 
OCPa Injectable IUD or 
Combined 
HC 
Borgdorff, 
2015 [37] 
166, HIV negative sex 
workers in Kigali 
Rwanda ages 18-49; 
N=47 incident HPV (any 
type) cases 
24M; 0M, 6M, 24M Linear Array HPV genotyping 
test (Roche) 
 
 
 
Age, education, years 
worked as sex 
worker, breast-
feeding, consistent 
condom use, 
antibiotic use past 14 
d, ever used 
antibiotics, time 
between assessments 
Non-
pregnant 
non-
hormonal 
user 
OCP on HPV (any 
type) aOR: 1.08 
(0.21, 5.44) 
HPV (any 
type) 
Injectable 
(any typeb) 
aOR: 0.79 
(0.34, 1.83) 
NA 
Harris, 
2009 [36] 
257, HIV negative 
women with no history 
of cervical neoplasia in 
the United States 
seeking routine care at 
family planning clinics, 
ages 18-50; N=152 
cases, N=107 controlsc 
Median follow-up: 
60D; 0M, and 
colposcopy biopsy 
visit 
PCR amplification, line blot 
assay (Roche) and histology 
assessment  
Age at colposcopy-
biopsy, lifetime 
number of male 
partners, and parity  
Cases: 
women with 
positive 
oncogenic 
HPV type; 
Controls: 
HPV-negative 
women with 
negative 
histology and 
cytology at 
both visits: 
HC reference 
group: never 
user of 
specific 
method   
Oncogenic HPV 
COC recent user: 
aOR: 0.6 (0.3, 
1.5); COC ≥1Yr: 
aOR: 0.8 (0.3, 
2.0); <1Yr: aOR: 
0.5 (0.2, 1.2); 
COC former user 
aOR: 0.9 (0.3, 
2.3) 
Oncogenic 
HPV DMPA 
recent userd 
aOR: 1.6 
(0.7, 3.7); 
≥1Yr 
DMPA: aOR: 
4.7 (1.4, 
15.8)*; <1Yr 
DMPA user: 
aOR: 0.7 
(0.3, 2.1); 
Former 
DMPA userd 
aOR: 1.3 
(0.6, 3.1) 
NA 
Gosvig, 
2013 [38] 
604, women with CIN2 
or worse at four 
hospitals in Denmark, 
age range NR; N=18 
cases of reappearance 
(2.2%) 
8-12M follow-up 
duration; 4-6M; 8-
12M 
Hybrid Capture 2; HPV 
genotype testing via line 
probe assay (INNO LiPAv2 
Innogenetics) 
Age, HPV viral load at 
baseline, condom use 
since last visit, # 
partners since last 
visit, time since last 
visit 
 
Non-user of 
oral 
contraception 
in last 4-6M 
OCP on re-
appearance of 
any HPV: aOR 
1.00 (0.21, 4.82) 
NA NA 
Lekovich, 
2015 [39] 
302, HIV negative 
women with IUD 
placement between 
2005 and 2012 and 
Mean time b/w 
pre-IUD and post 
IUD HR-HPV test: 
555 days (Copper 
Hybrid Capture 2 test 
 
Study groups 
matched on: age, 
high-risk HPV 
infection, rate of 
Non-
pregnant 
Copper IUD 
user 
NA NA HR-HPV: 
Levonorgestrel 
vs. Copper IUD 
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Study N, study sample Length of follow-
up; frequency STI 
assessment 
STI diagnostic test Covariates Reference 
Group 
OCPa Injectable IUD or 
Combined 
HC 
pre/post insertion HPV 
testing at participating 
U.S. institution, Mean 
age 33; N=8 /152 cases 
Levonorgestrel IUD, 
2/150 cases Copper IUD 
IUD), 534 days 
(Levonorgestrel 
IUD); IUD 
placement and 
repeat HR-HPV 
test: 356 (Copper 
IUD), 349 
(Levonorgestrel 
IUD) 
abnormal cytology 
and proportion of 
smokers 
OR: 4.11, 
p=0.056 
Louvanto, 
2011 [40] 
255, postpartum 
women in Finland, 
Mean age 26 (SD 3.1); 
N=203 incident cases, 
133 for HPV- species α7 
and α9 included in 
analyses  
6Y; 0M, 2M, 12M, 
24M, 36M, 6Y 
Multiplex-HPV genotyping kit 
(Progen Biotechnik GmbH)  
 
 
Age, HR-HPV 
seropositive at 
baseline, 
seroconverted to HR-
HPV, # sexual 
partners until age 20, 
lifetime # sex 
partners, age 
initiation of OC use, 
marital status, 
employment status, 
age of onset of sexual 
activity, baseline PAP 
smear results, 
baseline oral HR-HPV 
DNA status, 
frequency of sex, # of 
births, oral sex, ever 
had STD, history of 
genital warts, history 
of oral warts, age 
initiation of smoking, 
pregnancy during 
follow-up, change in 
marital status during 
follow-up 
 
Final model (empirical 
strategy): age, 
seroconverted to HR-
Never used 
OC pills 
OCP (ever use) 
on Species α7 
and α9 HR- HPV: 
aIRR: 
 (ns) NR 
(respectively) 
NA NA 
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Study N, study sample Length of follow-
up; frequency STI 
assessment 
STI diagnostic test Covariates Reference 
Group 
OCPa Injectable IUD or 
Combined 
HC 
HPV, # sexual 
partners until age 20, 
lifetime # sexual 
partners, age initiated 
OC use, smoking, 
pregnancy during 
follow-up, change in 
marital status during 
follow-up 
Marks, 
2011 [41] 
1135, HIV-negative 
women ages 20-37 in 
Thailand, reporting no 
commercial sex work in 
past 6M and willing to 
adhere to self-selected 
contraceptive method 
for at least 1Y; N=269 
(8%) incident cases for 
any HPV, 157 (4.7%) 
incident HR-HPV cases 
18M; 0M, 6M, 
12M, 18M 
QIAamp DNA Blood Kit 
(Qiagen), HPV Linear Array, 
PCR assay (Roche Diagnostics) 
 
Age, study site, # live 
births, male condom 
use P6M, age sexual 
debut, # lifetime 
partners, # partners 
P6M, smoking P6M, 
cervical cytology at 
enrollment and 
follow-up, BV at 
enrollment, prior STI 
infection, cervical 
ectopy 
 
Final model (empirical 
strategy): age, study 
site, # of lifetime and 
recent sexual 
partners, new sexual 
partner, concurrent 
BV, duration of HC 
use 
Non- 
hormonal 
user during 
same interval 
of 
assessment 
COC on HPV (any 
type) aOR: 1.27 
(0.93, 1.74); HR-
HPV aOR: 1.22 
(0.81, 1.83) 
DMPA on 
HPV (any 
type) aOR: 
0.90 (0.63, 
1.31), HR-
HPV aOR: 
0.87 (0.55, 
1.35) 
NA 
Moscicki 
2001 [26] 
105, women aged 13 to 
21 attending 2 family 
planning clinics in San 
Francisco, USA; N=54 
incident cases  
Median follow-up: 
50M [IQR: 23-
79M]; ~4-6M (9 
median visits, IQR: 
4-15) 
PCR assay; B-globin control; 
dot blot and Roche reverse 
blot method (Roche 
Molecular Systems) 
 
Rate of new partners 
per month since last 
visit, history of HSV, 
history of vulvar 
warts, lifetime sexual 
partners, marijuana 
use 
 
Non-current 
OCP user 
OCP on HPV (any 
type) aHR 0.49 
(0.28, 0.86)* 
NA NA 
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Study N, study sample Length of follow-
up; frequency STI 
assessment 
STI diagnostic test Covariates Reference 
Group 
OCPa Injectable IUD or 
Combined 
HC 
Final model: rate of 
new partners per 
month since last visit, 
history of HSV, history 
of vulvar warts. 
Nielsen, 
2009 [42] 
6246, women aged 20-
29 in Copenhagen, 
Denmark, randomly 
sampled from general 
population; N= 798 
(12.8%) HR-HPV incident 
cases 
2Y; 0M and 2Ye 
 
 
Hybrid Capture 2 and LiPA V2 
PCR assay (Innogenetics); B-
globin control 
 
 
Age, # sexual 
partners, marital 
status, self-reported 
history of chlamydia, 
self-reported history 
of genital warts, 
parity, current 
condom use, amount 
of smoking  
 
Final model (empirical 
strategy): age, # of 
sexual partners 
during follow-up, 
marital status, 
interaction between 
marital status and 
number of sexual 
partners during 
follow-up 
Current non- 
hormonal 
user  
OCP on HR-HPV: 
≤2Yr aOR: 1.01 
(0.68, 1.50), 3-
4Yr aOR: 1.39 
(0.98, 1.99); 5-
6Yr aOR: 1.44 
(1.00, 2.07); 7+Yr 
aOR: 1.66 (1.17, 
2.35)*, Per Yr): 
1.04 (0.98, 1.10) 
 
NA NA 
Phelan, 
2009 [43] 
220, HIV+ and HIV 
women ages 18+ who 
reported injection drug 
use in past 10 years in 
Baltimore, USA; Mean 
age 37 (SD 6.6); 
Detection of new type-
specific HPV cases 22% 
of 775 visits 
5Y; 0M and every 
6M 
PCR assay; B-globin controls, 
oligonucleotide dot blot 
hybridization 
  
Age, HIV status and 
CD4 category, 
smoking in P6M, 
injection drug use 
P6M, marijuana use 
P6M, any STD P6M, # 
male sex partners 
P6M, # male sex 
partners P10Y, # live 
lifetime births 
 
Final model (empirical 
and theoretical 
approach): age, HIV 
Never user of 
OC (lifetime) 
OCP (ever): Not 
significant at 
univariate level 
(among HIV+ or 
HIV- women) so 
multivariate not 
reported 
NA NA 
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Study N, study sample Length of follow-
up; frequency STI 
assessment 
STI diagnostic test Covariates Reference 
Group 
OCPa Injectable IUD or 
Combined 
HC 
status and CD4 level, 
crack use in P6M, # of 
male sex partners in 
P10Y 
Sellors, 
2003 [28] 
253, Canadian women 
ages 15 to 49 
in selected physician 
practices; 28 incident 
HPV cases (11.1%) 
1Y; 0M and 12M PCR assay with HPV-
genotyping; HCII assay for HR-
HPV detection 
Age, median number 
of sex partners in the 
last year, median 
number of lifetime 
sex partners, marital 
status, smoking status 
Non-OCP user OCP on HR-HPV 
aOR: 0.70 (0.20, 
2.0) 
NA NA 
Shew, 
2015 [44] 
150, adolescents ages 
14-17 in Indianapolis, 
U.S. visiting one of 3 
primary care clinics 
Mean follow-up: 
5.8Y (3.9-9.2); 
Every 3M 
Linear array HPV genotyping 
test (Roche Diagnostics) and 
PCR assay with B-globin 
control 
 
STIs (clinic test): CT, 
NG and TV; 
contraceptive use, 
condom use, coital 
frequency, number 
of partners 
Non-user of 
OCP in last 
3M, Non-
user of 
DMPA in last 
3M, 
respectively 
OCP on HPV (all 
types) aHR: 2.0 
(1.28, 3.15)*; 
HR-HPV aHR: 
1.31 (0.73, 
2.35); LR-HPV 
aHR: 2.73 (1.52, 
4.90)* 
 
DMPA on 
HPV (all 
types) aHR: 
0.96 (0.67, 
1.38); HR-
HPV aHR: 
0.80 (0.54, 
1.19); LR- 
HPV aHR: 
1.57 (0.90, 
2.75) 
NA 
Winer, 
2003 [27] 
553, university women 
in Seattle, USA ages 18-
20; incident cases (all 
HPV type) among OCP 
users: 92 per 503 PY vs. 
56/553 PY among non-
OCP users 
5Y; 4M intervals PCR assay and dot-blot 
hybridization with B-globin 
control 
Time interval, current 
smoking, history of 
non-genital warts, 
history of tampon 
use, being delivered 
by cesarean section, 
length of time having 
known a partner, 
partner’s ethnicity, 
partner’s age, 
partner’s educational 
level, partner’s 
lifetime number of 
partners, partner’s 
circumcision status, 
condom use with a 
new partner.  
Non-OCP 
user 
OCP on HPV (all 
types) aHR: 1.40 
(1.01, 1.80)* 
NA NA 
 28 
Study N, study sample Length of follow-
up; frequency STI 
assessment 
STI diagnostic test Covariates Reference 
Group 
OCPa Injectable IUD or 
Combined 
HC 
Whether partner had 
ever had a STI, 
subject/partner 
alcohol use during 
sex. 
 
Final model: no. sex 
partners, condom use 
with new partners, 
sex partner’s no. of 
other partners, new 
partner in past 12 M, 
time knowing partner 
before sex, current 
smoker 
Winer, 
2016 [45] 
420, women aged 25-65 
in the USA sampled 
from internet dating 
group; cumulative 
incidence of HR-HPV: 
25.4% 
Mean follow-up: 
12.5M +/- 5M; 
Mean interval b/w 
assessment: 5.1M 
+/- 1.4M 
PCR assay with B-globin 
controls, Roche Linear Array 
genotyping test 
 
Age at first sex, (time 
dependent variables): 
age, marital status, 
smoking history, 
abnormal PAP history, 
current HC use, 
menopausal status, 
sex with ≥1 male 
partner in past 6M, 
lifetime # sex partners 
 
Final model (empirical 
strategy): lifetime # of 
male sex partners, 
and male sex partners 
in the P6M (women 
with ≥1 partner in 
P6M)   
Current non-
hormonal 
user  
NA NA Any HC use on 
HR-HPV, all 
women aHR: 
1.82 (1.17, 
2.83)*; 
Women with 
no sex 
partners in 
P6M aHR: 4.16 
(1.27, 13.63)*; 
Women with 
≥ 1 partner in 
P6M aHR: 1.65 
(1.05, 2.59)* 
Notes: PY: person-years at risk; aOR: adjusted odds ratio; aHR: adjusted hazard ratio. HR-HPV: high-risk HPV, LR-HPV: low-risk HPV. *p<0.05; #p=0.056;  
a OCP type was unspecified unless COC (combined oral contraception) or POP (progestin-only pill) is noted.  
b Injectable type not reported but authors note most commonly DMPA in setting with occasional norethisterone enanthate (NE-ENT) use. 
c Case control study. 
d Former user defined as having stopped using method at least one year before colposcopy-biopsy. Recent use defined as having used that method within 6 months of biopsy. 
e Contraceptive use exposure period retrospectively recalled, exceeds study follow-up duration. 
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Table 2. Prospective associations between hormonal contraceptive use and herpes simplex virus type 2 (HSV-2) (N=4).  
Study N, study 
sample 
Length of 
follow-up; 
frequency 
STI 
assessment 
STI 
diagnostic 
test 
Length of 
follow-up; 
frequency 
STI 
assessment 
Covariates Reference 
group 
OCPa Injectable Combined 
HC 
Borgdorff, 
2015 [37] 
163, HIV-
negative sex 
workers in 
Kigali, Rwanda 
ages 18 to 49, 
N=21 HSV-2 
incident casesc 
24M; 0M, 
3M, 6M, 
12M, 24M 
 
HerpeSelect 2 
ELISA (index 
≥3.5 defined 
as positive) 
24M; 0M, 
3M, 6M, 
12M, 24M 
 
 
Age, education, years worked 
as sex worker, breast-feeding, 
consistent condom use, 
antibiotic use past 14 d, ever 
used antibiotics, time duration 
between assessments 
Non-
pregnant 
non-
hormonal 
user 
OCP aOR: 
4.28 (0.07, 
262.1) 
Injectable (type 
not specifiedd) 
aOR: 6.34 (0.25, 
158.5) 
 
NA 
Chohan, 
2009 [53] 
297, HIV-
negative sex 
workers in 
Mombasa, 
Kenya ages 18 
to 46, N=115 
HSV-2 incident 
cases (23 cases 
per 100 PY)b 
 
 
13Y; every 
1M (median 
time b/w 
visits: 33d 
[IQR 28-48] 
 
HSV-2- type-
specific HSV-2 
gG based 
ELISA (index 
value of >1.1 
defined as 
positive) 
 
13Y; every 
1M (median 
time b/w 
visits: 33d 
[IQR 28-48] 
 
 
Education, parity, alcohol and 
tobacco use, vaginal washing 
practices, bar vs. night club 
work. Time-dependent 
variables: age, duration of sex 
work, presence of other genital 
tract infections, # sex partners 
per week, condom use during 
past working week 
 
Final model: duration of sex 
work, bar (vs. night club) work, 
# sex partners per week, 
percentage condom use past 
week, presence of BV  
Non-
hormonal 
user  
OCP aHR: 
0.50 (0.23, 
1.08)# 
NA aHR 
Norplant/ 
DMPA 
(combined): 
0.92 (0.53, 
1.61) 
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Study N, study 
sample 
Length of 
follow-up; 
frequency 
STI 
assessment 
STI 
diagnostic 
test 
Length of 
follow-up; 
frequency 
STI 
assessment 
Covariates Reference 
group 
OCPa Injectable Combined 
HC 
Grabowski, 
2015 [35] 
682, HIV-
negative 
women in Rakai, 
Uganda ages 15 
to 49 who had a 
HIV-negative 
male partner, 
N=52 HSV-2 
incident casese 
3Y; 0M, 12M 
& 24M 
 
HSV-2 ELISA 
test 
3Y; 0M, 12M 
& 24M 
 
Age, education of woman and 
male partner, # of lifetime 
sexual partners. Time-varying 
variables: male circumcision, 
coital frequency, and female 
and male self-report of any 
condom use and non-marital 
partners in the past year.  
 
Final model: did not include 
coital frequency or male 
circumcision based on model 
fit 
Non-
pregnant 
non-
hormonal 
user  
OCP aHR: 
0.49 (0.08, 
3.01) 
Consistent 
DMPA users 
aHR: 2.26 (1.09, 
4.69)*; Initiated 
DMPA aHR: 0.75 
(0.29, 1.92); 
Discontinued 
DMPA use aHR: 
0.58 (0.13,2.51) 
NA 
Socias, 
2017 [54] 
149, HIV-
positive (N=13) 
and HIV-
negative 
(N=136) sex 
workers in 
Vancouver, 
Canada ages 
14+, N=39 HSV-
2 incident cases; 
17.1 cases per 
100 PY (12.4, 
23.6) 
 
4Y; every 4M 
 
Serum 
samples via 
non-specific 
EIA HSV IgG. 
If reactive, 
anti-HSV-2 
using TSS 
Focus 
HerpeSelect-
2 IgG EIA 
(Focus 
Diagnostics) 
 
4Y; every 4M 
 
 
Time invariant: Age, indigenous 
ancestry, education. Time-
varying: HIV status, incident 
STIs (T. pallidum, NG and CT), 
average # of clients per week, # 
male non-commercial partners, 
inconsistent use of condoms by 
clients and non-clients, 
respectively, type of sex work 
venue 
 
Final model (stepwise 
selection): type of sex work 
venue 
Non-DMPA 
user in prior 
6M 
NA HIV positive and 
negative DMPA 
users aHR: 4.43 
(1.90, 10.35)*; 
HIV negative 
DMPA users 
aHR: 3.97 (1.64, 
9.60)* 
 
NA 
Notes: PY: person-years at risk. * Statistically significant at p<0.05. # Marginally significant at p=0.08; 
a OCP type was unspecified unless COC (combined oral contraception) or POP (progestin-only pill) is noted. 
b 10 women seroconverted to HSV-2 & HIV-1 at same visit; PY: person-years; NA: not assessed by study. 
c Women censored after first incident infection. 
d Injectable type not reported but authors note most commonly DMPA in setting with occasional norethisterone enanthate use. 
e Excluding incident cases among pregnant women. 
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Table 3. Prospective associations between hormonal contraceptive use and Chlamydia trachomatis (CT) (N=9). 
Study N, study sample, N of 
incident cases or 
incident rate 
Length of 
follow-up; 
frequency STI 
assessment 
STI Diagnostic 
test 
Covariates  Reference 
group 
OCPa Injectable Implant 
Borgdorff, 
2015 [37] 
397, HIV-negative sex 
workers in Kigali, Rwanda 
ages 18-49; N=30 incident 
casesb,e 
12M; 0M, 6M, 
12M 
 
 
Endocervical 
swabs via 
Amplicor CT/NG 
PCR test (Roche 
Diagnostics) 
 
Age, education, years worked as 
sex worker, breast-feeding, 
consistent condom use, antibiotic 
use past 14 d, ever used 
antibiotics, time duration 
between assessments 
Non-pregnant 
non-hormonal 
user  
OCP aOR: 6.13 
(1.5, 23.8)* 
Injectable 
(type not 
specifiedd) 
aOR:  2.24 
(0.69, 7.29) 
 
NA 
Baeten, 
2001 [21] 
948, HIV-1 negative sex 
workers in Mombasa, 
Kenya ages 16-48; N=175 
incident cases (11.1/100 
PY) 
Range 15 to 
2366 days 
(median: 421 
days); median 
time b/w visits: 
35 days 
Enzyme-linked 
immunoabsorbe
nt assay (ELISA) 
(Microtrak) 
Age, years of education, years of 
prostitution, parity, number of 
sexual partners, place of work (ie, 
bar vs. nightclub), number of 
sexual contacts, and condom 
usage 
No 
contraceptives 
or tubal 
ligation 
OCP aHR: 1.8 
(1.1, 2.9)* 
DMPA aHR: 1.6 
(1.1, 2.4)* 
NA 
Kapiga, 
2009 [47] 
958, HIV negative women 
ages 16 to 62 in Lusaka, 
Zambia (ZA), Moshi 
Tanzania (TZ) and 
Durban/Hlabisa, South 
Africa (SA); Incidence rate 
b: 19.5/100 PYAR (SA); 
4.9/100 PYAR (TZ, ZA) 
 
12M, every 3M 
 
 
TZ/ZA site: 
endocervical 
swabs via 
enzyme-linked 
immunosorbent 
assay (ELISA), 
(Murex 
Biotech); SA 
site: urine 
samples via BD 
Probe Tec ET 
assayc  
 
 
Age, site, partner earns income, # 
sex partners, frequency vaginal 
sex in past 1W, anal sex in past 
3M, other STIs, bacterial 
vaginosis, candida, abnormal 
vaginal discharge on exam, 
abnormal cervical discharge on 
exam, incident HIV  
 
Final model (empirical approach): 
site, age, # sex partners, incident 
HIV infection and N. gonorrhoeae 
infection (SA model); site, 
presence of candida and 
abnormal vaginal discharge on 
exam (TZ/ZA model) 
Not specified OCP 
Durban/Hlabis
,SA aOR: NR 
(ns); Moshi 
TZ/Lusaka ZA 
site aOR: NR 
(ns) 
DMPA 
Durban/Hlabis,
SA aOR: 1.8 
(1.0, 3.3)*; 
DMPA Moshi 
TZ/Lusaka ZA 
site aOR: NR 
(ns) 
 
Norplant 
Durban/Hlabis,S
A aOR: NR (ns); 
Norplant Moshi 
TZ/Lusaka ZA 
site aOR: NR (ns) 
 
Louv, 
1989 [23] 
818, U.S. women ages 19 
to 29 attending a STI clinic 
in Birmingham Alabama; 
N=214 incident cases b  
6M; Monthly Fluorescein-
tagged 
antibody; 
Microtrak 
Culture 
confirmation 
(Syva CO) 
Age, mean number of sex acts 
per month, mean number of 
partners during follow-up period, 
parity, gravidity 
Tubal ligation 
or IUD user 
COC: aHR: 
1.73 (1.08, 
2.77)* 
 
 
NA NA 
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Study N, study sample, N of 
incident cases or 
incident rate 
Length of 
follow-up; 
frequency STI 
assessment 
STI Diagnostic 
test 
Covariates  Reference 
group 
OCPa Injectable Implant 
Lavreys, 
2004  [22] 
242, HIV-1 positive 
commercial sex workers 
attending STI clinic in 
Mombasa, Kenya; N=26 
incident cases, incidence 
rate: 7.7/100 PY 
Median follow-
up 35M (IQR: 
11-62M); Every 
1M 
Antigen test by 
ELISA 
(Microtrak, 
Syva) 
Age, years of education, years of 
sex work, parity, workplace, 
number of sexual partners per 
week, condom use 
No 
contraception 
or tubal 
ligation 
OCP: aHR 2.20 
(0.70, 7.30) 
DMPA: aHR 
3.10 (1.0, 9.4)# 
NA 
Masese, 
2013 [51] 
 
865, HIV positive and HIV-
negative women who 
report engaging in 
transactional sex, ages 18 
to 50 in Mombasa, Kenya; 
N=101 incident casesb, 
incidence rate = 5.0/100 
PY 
4Y, every 1-3M 
 
 
Endocervical 
swab via  
Gen-Probe 
Aptima GC/CT 
Detection 
System 
Age, vaginal microbiota, place of 
work (bar vs. nightclub or home 
based/ other), educational level, 
marital status, unprotected 
intercourse in past wk, # of sex 
partners in past wk, vaginal 
washing, presence of other 
genital tract infections (T. 
vaginalis, C. albicans, N. 
gonorrhoeae), HIV-1 serostatus, 
and cervical ectopy 
 
Final model (empirical approach): 
Age, unprotected sex with >1 sex 
partner in past week, HIV status, 
N. gonorrhoeae infection 
Non-hormonal 
user  
OCP aHR: 0.2 
(0.0, 1.7) 
DMPA aHR: 1.8 
(1.1, 3.0)* 
 
 
NA 
Pettifor, 
2009 [48] 
567, HIV-negative women 
ages 18 to 40 recruited 
from family planning 
clinics in Orange Farm, 
South Africa; N=119 
incident cases b, incident 
rate: 28.2 per 100 PY 
1Y; every 3M 
 
  
Urine sample via 
ligase chain 
reaction (LCx®; 
Abbot 
Laboratories) 
 
Age, relationship status, 
education, frequency of sex in 
the past 3M, # partners in the 
past 3M, condom use in the past 
3M, vaginal douching past 3M, 
age of first sex  
 
Final model (empirical and 
theoretical approach): Age, 
education, condom use 
consistency in past 3M 
Non- pregnant, 
non-hormonal 
user 
NA DMPA aIRR: 
1.24 (0.80, 
1.94); NET-EN 
aIRR: 0.91 
(0.59, 1.43) 
NA 
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Study N, study sample, N of 
incident cases or 
incident rate 
Length of 
follow-up; 
frequency STI 
assessment 
STI Diagnostic 
test 
Covariates  Reference 
group 
OCPa Injectable Implant 
Romer, 
2013 [50] 
342, adolescent girls ages 
14-17 attending clinics in 
inner-city areas of 
Indianapolis, USA; N=165 
incident cases b 
Originally 27M, 
extended to 5Y 
for some 
participants; 
every 3M 
 
Clinician 
obtained 
cervical samples 
or self-obtained 
vaginal swabs 
via nucleic acid 
amplification 
tests (NAATs)  
(Amplicor PCR, 
Roche 
Diagnostics) 
Age, positive STI test at start of 
period, # of partners in past 3M, 
# of lifetime partners, # of sexual 
events in last 3M (diary period), # 
of unprotected sexual events in 
last 3M (diary period) 
 
Non-hormonal 
user 
NA DMPA, use in 
past 3M aOR: 
0.76 (0.45, 
1.31); DMPA 
used 3-6M ago 
aOR: 1.17 
(0.69, 1.96) 
NA 
Russell, 
2016 [52] 
225, HIV-negative women 
recruited from outpatient 
clinics ages 15-35 who 
had lower genital tract 
infection or were 
biologically at risk of STI 
infection from Pittsburgh 
PA, USA; Incidence rate: 
48 women tested positive, 
28 per 100 PYc incident 
rate 
 
Median 12M 
FU; 0M, 1M, 
4M, 8M, 12M 
 
Endocervical 
swab via 
nucleic acid 
amplification 
tests (NAATs) 
Age, education, site of C. 
trachomatis (CT) infection at 
enrollment (cervix vs. 
cervix/endometrium, or 
uninfected), GN infection during 
follow-up, STI diagnosis among 
partner during follow-up, # of 
male partners since last visit, new 
male partners since last visit, sex 
with uncircumcised male in last 
3M, condoms (reported at any 
visit) 
 
Final model (empirical approach): 
age, N. gonorrhoeae during 
follow-up, site of CT infection, CT 
infection by partner during 
follow-up, new male partner 
since last visit, sex with 
uncircumcised male last 3M 
Non-user of 
OCP or DMPA, 
respectively 
OCP aHR: NR 
(ns) 
DMPA aHR: 
1.03 (0.59, 
1.78) 
 
NA 
Notes: PY: person-years at risk. * Statistically significant at p<0.05. # p=0.05 
a OCP type was unspecified unless COC (combined oral contraception) or POP (progestin-only) is noted.  
b Multiple incident cases per woman were allowed, i.e., incident cases defined as a positive test following a negative test. 
c Incident infection defined as any positive test during follow-up. 
d Injectable type not reported but authors note most commonly DMPA in setting with occasional norethisterone enanthate (NE-ENT) use. 
e Excluding cases among pregnant women.   
 34 
Table 4. Prospective associations between hormonal contraceptive use and Neisseria gonorrhoeae (NG) (N=7).  
Study N, study sample Length of 
follow-up; 
frequency 
STI 
assessme
nt 
STI 
diagnostic 
test 
Covariates Reference 
group 
OCPa Injectable Implant 
Borgdorff, 
2015 [37] 
381, HIV-negative 
sex workers in 
Kigali, Rwanda 
ages 18 to 49, 
N=42  incident 
cases b,d 
12M; 0M, 
6M, 12M 
 
 
Endocervical 
swab via 
Amplicor 
CT/NG PCR 
test (Roche 
Diagnostics) 
Age, education, years worked as 
sex worker, breast-feeding, 
consistent condom use, 
antibiotic use past 14 d, ever 
used antibiotics, time duration 
between assessments 
Non-pregnant  
non-hormonal 
user 
OCP aOR: 2.57 
(0.78, 8.45) 
Injectable (type 
not specifiedc) 
aOR: 0.80 
(0.28, 2.31) 
 
NA 
Baeten, 
2001 [21] 
948, HIV-1 
negative sex 
workers in 
Mombasa, Kenya 
ages 16-48; N=272 
incident cases 
(16.5/100 PY) 
Range 15 to 
2366 days 
(median: 
421 days); 
median 
time b/w 
visits: 35 
days 
Culture on 
Thayer-
Martin 
media 
Age, years of education, years of 
prostitution, parity, number of 
sexual partners, place of work 
(ie, bar vs. nightclub), number of 
sexual contacts per week, and 
condom usage 
No 
contraception or 
tubal ligation 
OCP aHR: 1.4 
(0.9, 2.1) 
DMPA aHR: 1.1 
(0.8, 1.6) 
NA 
Louv 1989 
[23] 
818, U.S. women 
ages 19 to 29 
attending a STI 
clinic in 
Birmingham 
Alabama; N=155 
incident cases b 
6M; 
Monthly 
Gram stain 
or oxidase 
reagent 
(Marion 
Scientific), 
confirmation 
by Rapid NH 
system 
(Innovative 
Diagnostic 
Systems) 
Age, mean number of sex acts 
per month, mean number of 
partners during follow-up period, 
parity, gravidity 
Tubal ligation or 
IUD user 
COC:  aHR: 1.70 
(1.05, 2.76)* 
NA NA 
Lavreys 
2004 [22] 
242, HIV-1 positive 
commercial sex 
workers attending 
STI clinic  in 
Mombasa, Kenya; 
N=119 incident 
cases, incidence 
rate: 14.9/100 PY 
Median 
follow-up 
35M (IQR: 
11-62M); 
Every 1M 
Antigen test 
by ELISA 
(Microtrak, 
Syva) 
Age, years of education, years of 
sex work, parity, workplace, 
number of sexual partners per 
week, condom use 
No 
contraception or 
tubal ligation 
OCP: aHR 0.6 
(0.3, 1.3) 
DMPA: 1.0 (0.6, 
1.7) 
NA 
 35 
Study N, study sample Length of 
follow-up; 
frequency 
STI 
assessme
nt 
STI 
diagnostic 
test 
Covariates Reference 
group 
OCPa Injectable Implant 
Kapiga, 
2009 [47] 
958, HIV negative 
women ages 16 to 
62 in Lusaka, 
Zambia (ZA), 
Moshi Tanzania 
(TZ) and 
Durban/Hlabisa, 
South Africa (SA), 
Incidence ratea: 
16.5/100 PYAR 
(SA); 5.3/100 PYAR 
(TZ, ZA) 
12M; every 
3M 
 
 
TZ and ZA: 
culture 
methods 
used. SA: 
urine sample 
via BD Probe 
Tec ET assay 
Age, site, partner earns income, 
# sex partners, frequency vaginal 
sex past 1W, anal sex past 3M, 
other STIs, BV, candida, 
abnormal vaginal discharge on 
exam, abnormal cervical 
discharge on exam, incident HIV 
 
Final model (empirical 
approach):  site and incident HIV 
infection (SA model); age (TZ/ZA 
model) 
Not specified OCP 
Durban/Hlabisa 
SA site: aOR: 
NR (ns); Moshi 
TZ/Lusaka ZA 
site aOR: NR 
(ns) 
DMPA 
Durban/Hlabisa 
SA site: aOR: 
NR (ns); Moshi 
TZ/Lusaka ZA 
site aOR: NR 
(ns) 
 
 
Norplant 
Durban/Hlabisa 
SA site: aOR: 
NR (ns); Moshi 
TZ/Lusaka ZA 
site aOR: 4.7 
(1.3, 16.5)* 
 
Pettifor, 
2009 [48] 
567, HIV-negative 
women ages 18 to 
40 recruited from 
family planning 
clinics in Orange 
Farm, South Africa; 
N=45 incident 
cases b incident 
rate: 9.9 per 100 
PY 
1Y; 0M, 
2M, 6M, 
8M and 
12M (NET-
EN users) 
or 0M, 3M, 
6M, 9M 
and 
12M 
(DMPA 
users and 
controls) 
Urine sample 
via 
ligase chain 
reaction 
(LCx®; Abbot 
Laboratories) 
 
Age, relationship status, 
education, frequency of sex past 
3M, # sex partners past 3M, 
condom use past 3M, vagina 
douching past 3M, age of first 
sex  
 
Final model (empirical and 
theoretical approach): Age, 
education and condom use 
consistency in past 3M 
Non-pregnant  
non-hormonal 
user 
NA DMPA aIRR: 
1.30 (0.58, 
2.98); NET-EN 
aIRR: 1.11 
(0.55, 2.25) 
NA 
Romer, 
2013 [50] 
342, adolescent 
girls ages 14-17 
attending clinics in 
inner-city areas of 
Indianapolis, USA; 
N=65 incident 
cases b 
Originally 
27M, 
extended 
to 5Y for 
some 
participants
; every 3M 
 
 
Nucleic acid 
amplification 
tests  
(Amplicor 
CT/NG PCR; 
Roche 
Diagnostics). 
Positive 
results 
confirmed by 
Gen-Probe 
Age, positive STI test at start of 
period, # of sexual partners in 
past 3M, # of lifetime sexual 
partners, # of sexual events in 
last 3M (diary period), # of 
unprotected sexual events in last 
3M (diary period) 
 
Non-hormonal 
user  
NA DMPA use in 
current 3M 
period aOR: 
1.19 (0.57, 
2.48); DMPA 
use in prior 3M 
aOR: 1.12 
(0.54, 2.32) 
NA 
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Notes: PY: person-years at risk. * Statistically significant at p<0.05.  
a OCP type was unspecified unless COC (combined oral contraception) or POP (progestin-only pill) is noted.  
b Multiple incident cases per woman were allowed, i.e., incident cases defined as a positive test following a negative test. 
c Injectable type not reported but authors note most commonly DMPA in setting with occasional norethisterone enanthate use. 
d Excludes cases among pregnant women. 
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Table 5. Prospective associations between hormonal contraceptive use and Chlamydia trachomatis (CT) or Neisseria  
gonorrhoeae (NG) (combined) (N=2).  
Study N, study 
sample 
Length of 
follow-up; 
frequency STI 
assessment 
STI diagnostic 
test 
Covariates Reference 
group 
OCPa Injectable Implant 
Low 2014 
[55] 
172, HIV-1 
positive women 
on antiretrovirals 
who engage in 
transactional sex 
in Bobo-
Dioulasso 
Burkina Faso, 
ages 18 to 50, 
N=11 incident 
cases GN; rate of 
2.76 cases per 
100 PY; 3 incident 
cases CT, rate of 
0.75 per 100 PY b 
4Y; 0M, ~3-6M 
 
Cervical swab 
via PCR 
(Amplicor 
CT/NG PCR 
assay, Roche) 
using pooling 
approach 
Age, education, tobacco use, # 
sex acts past wk, alcohol use, 
sex work, condom use, vaginal 
washing, antibiotic use past 1M, 
abnormal vaginal discharge on 
exam, genital ulcers on exam, 
abnormal cervical exam, genital 
warts, concurrent BV, T. 
vaginalis, Candida albicans, or 
HSV-2 DNA, presence of Y-PCR, 
HIV-1 plasma viral load, HIV-1 
eCVL RNA detected, CD4 count, 
time since sample 
collection, antiretroviral status 
 
Final model (empirical and 
theoretical approach): # sex acts 
past wk, CD4 count, education 
Non-hormonal 
user  
OCP aOR: ns 
(NR)  
DMPA  on 
NG/CT aOR: 
5.83 (0.90, 
37.70) 
NA 
Morrison 
2004 [25]  
819, women 
attending 2 
reproductive 
health clinics in 
Baltimore, USA 
ages 15 to 45. 
N=45 incident 
cases of CT or 
GN; 6.2 per 100 
PY. 
3, 6 and 12M CT by ligase 
chain reaction 
(LCx; Abbott 
Laboratories). 
GN by Gram 
stain, oxidase 
reaction, 
lactamase 
and production. 
Confirmation by 
Gonocheck II (E-
Y Laboratories). 
Age, race, and site and 
measures of contraceptive 
exposure.  
Non-hormonal 
user 
COC aHR: 1.5 
(0.6, 3.5) 
DMPA: aHR: 
3.6 (1.6, 8.5) 
NA 
Notes: PY: person-years at risk. * Statistically significant at p<0.05.  
 a OCP type was unspecified unless COC (combined oral contraception) or POP (progestin-only pill) is noted.  
b Incidence is new cases of NG or CT during study period, divided by number of women at risk; cases at baseline excluded.  
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 Table 6. Prospective associations between hormonal contraceptive use and Treponema pallidum (syphilis) (N=3).  
Study (N), study 
sample 
Length of 
follow-up; 
frequency 
STI 
assessment 
STI diagnostic test Covariates Reference 
group 
OCPa Injectable Implant 
Borgdorff, 
2015 [37] 
354, HIV-negative 
sex workers in 
Kigali, Rwanda 
ages 18 to 49, N=4  
incident cases b 
12M; 0M, 
6M, 12M 
 
 
 
Spinreact Raplid Plasma 
Reagin test, 
confirmation by 
Spinreact T. pallidum 
Haemagglutination test  
Age, education, years worked as 
sex worker, breast-feeding, 
consistent condom use, antibiotic 
use past 14 d, ever used 
antibiotics, time duration 
between assessments 
Non-pregnant 
non-hormonal 
user 
NA Injectable 
(type not 
specifiedb) 
aOR: 1.43 
(0.11, 19.1) 
 
NA 
Baeten, 
2001 [21] 
948, HIV-1 
negative sex 
workers in 
Mombasa, Kenya 
ages 16-48; N=48 
incident cases 
(2.9/100 PY) 
Range 15 to 
2366 days 
(median: 421 
days); median 
time b/w 
visits: 35 days 
Hemagglutination assay 
(Biotech Laboratories) 
Age, years of education, years of 
prostitution, parity, number of 
sexual partners, place of work (ie, 
bar vs. nightclub), number of 
sexual contacts per week, and 
condom usage 
Non-hormonal 
user or tubal 
ligation 
OCP aHR: 
0.40 (0.10, 
1.50) 
DMPA aHR: 
0.50 (0.20 
1.4) 
NA 
Kapiga, 
2009 [47] 
958, HIV negative 
women from 
general 
population ages 
16 to 62 in Lusaka, 
Zambia (ZA), 
Moshi Tanzania 
(TZ) and 
Durban/Hlabisa, 
South Africa (SA), 
Incidence rate b: 
7.5/100 PY (all 
sites) 
 
 
12M; every 
3M 
 
 
Positive serum reaction 
after both a rapid 
plasma reagin card test 
and treponema 
pallidum 
haemagglutination 
assay (TPHA) or 
microhaemagglutination 
assay-treponema 
pallidum (MHA-TP) 
 
Age, site, partner earns income, # 
sex partners, frequency vaginal 
sex in past wk, anal sex in past 
3M, other STIs, bacterial 
vaginosis, candida, abnormal 
vaginal discharge on exam, 
abnormal cervical discharge on 
exam, incident HIV infection 
 
Final model (empirical selection): 
site, age, husband/partner earns 
income, frequency of vaginal sex 
past wk, T. vaginalis 
Not specified OCP All 
sites aOR: 
NR (ns) 
All sites, 
DMPA: 
aOR: NR 
(ns) 
 
All sites, 
Norplant 
aOR: NR 
(ns) 
 
Notes: PY: person-years at risk. * Statistically significant at p<0.05.  
a OCP type was unspecified unless COC (combined oral contraception) or POP (progestin-only pill) is noted.  
b Multiple incident cases per woman were allowed; included positive serology results from baseline, incident cases defined as a positive test following a negative test. 
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Table 7. Prospective associations between hormonal contraceptive use and T. vaginalis (TV) (N=9).  
Study N, study sample Length of 
follow-up; 
frequency 
STI 
assessment 
STI diagnostic 
test 
Covariates Reference 
group 
OCPa Injectable Implant or 
combined 
HC 
Balkus, 2014 
[34] 
2920, HIV-
negative women 
ages 18+ with no-
drug use in past 
12M in Blantyre, 
Lilongwe Malawi; 
Durban, Hlabisa, 
South Africa; 
Philadelphia USA; 
Lusaka Zambia; 
Harare, 
Chitungwiza, 
Zimbabwe, 
Detection at 
N=400 of 16,259 
visitsd 
12 to 30 M; 
0M, 12M, 
30M (or 
study exit) 
Vaginal wet 
mount via saline 
microscopy 
Age, marital status, 
unprotected sex in the last 
week, T. vaginalis at 
baseline, intermediate 
Nugent score, BV at prior 
visit 
 
 
Non-pregnant 
non-hormonal 
user 
OCP aHR: 0.64 
(0.47, 0.89)* 
Injectable 
(type not 
specified) 
aHR: 0.60 
(0.47, 0.78)* 
Implant (type 
not specified) 
aHR: 0.57 
(0.20, 1.60) 
 
 
Baeten, 
2001 [21] 
948, HIV-1 
negative sex 
workers in 
Mombasa, Kenya 
ages 16-48; 
N=435 incident 
cases (26.4/100 
PY) 
Range 15 to 
2366 days 
(median: 
421 days); 
median time 
b/w visits: 
35 days 
Vaginal wet 
mount 
Age, years of education, 
years of prostitution, parity, 
number of sexual partners, 
place of work (ie, bar vs. 
nightclub), number of sexual 
contacts per week, and 
condom usage 
Non-hormonal 
user or tubal 
ligation 
OCP aHR: 0.90 
(0.70, 1.30) 
DMPA aHR: 
0.60 (0.40 
1.0)* 
NA 
Barbone 
[24] 
818, U.S. women 
ages 19 to 29 
attending a STI 
clinic in 
Birmingham 
Alabama; N=171 
incident casese 
 
 
6M; Monthly Vaginal wet 
mount 
Spermicide use, sexual 
activity, age, race 
Tubal ligation or 
IUD user 
OCP: aHR 0.56 
(0.39, 0.81)* 
NA NA 
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Study N, study sample Length of 
follow-up; 
frequency 
STI 
assessment 
STI diagnostic 
test 
Covariates Reference 
group 
OCPa Injectable Implant or 
combined 
HC 
Borgdorff, 
2015 [37] 
381, HIV-negative 
sex workers in 
Kigali, Rwanda 
ages 18 to 49, 
N=89 incident 
casesb 
24M; 0M, 
6M, 12M, 
24M 
 
 
Vaginal swab via 
culture kit 
(InPouch, BioMed 
Diagnostics) and 
Gram stain 
(presence of 
>20% clue cells 
and Nugent 
criteria). 
Considered 
positive if tested 
positive on either 
test. 
Age, education, years 
worked as sex worker, 
breast-feeding, consistent 
condom use, antibiotic use 
past 14 d, ever used 
antibiotics, time duration 
between assessments 
Non-pregnant 
non-hormonal 
user  
OCP aOR: 0.61 
(0.20, 1.84) 
Injectable 
(type not 
specifiedf) 
aOR: 0.44 
(0.17, 1.10) 
 
 
NA 
Brahmbhatt, 
2014 [46] 
2374, HIV+ (304) 
and HIV- (2070) 
women ages 15 
to 49 in rural 
Rakai, Ugandac; 
N=96/2374 cases; 
2.4/100 PY 
12M; 0M, 
12M 
Self-collected 
vaginal swab via 
culture kit 
(InPouch, TV, 
BioMed 
Diagnostics) 
10-year age group, marital 
status, education, # sex 
partners past 12M, SES 
(home building materials), 
Nugent score for BV, 
condom use, syphilis result, 
HIV status 
 
Final model (empirical and 
theory informed): age, 
marital status, education, 
SES, condom use and other 
STIs, interaction b/w HC use 
and HIV status 
 
 
 
 
 
 
 
No method 
(neither 
hormonal or 
condom)  
COC past 12M 
aIRR: 1.02 (0.40, 
2.59); 
Consistently 
used COC (at 
baseline and 
follow-up) aIRR: 
1.07 (0.25, 4.56) 
DMPA past 
12M aIRR:  
0.54 (0.30, 
0.98)*; 
Consistently 
used DMPA 
only (at 
baseline and 
follow-up) 
aIRR: 0.59 
(0.28, 1.26) 
Norplant past 
12M aIRR: 
3.01 (1.07, 
8.49)*; 
Consistently 
used 
Norplant only 
(at baseline 
and follow-
up) aIRR: 3.13 
(1.08, 9.07)* 
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Study N, study sample Length of 
follow-up; 
frequency 
STI 
assessment 
STI diagnostic 
test 
Covariates Reference 
group 
OCPa Injectable Implant or 
combined 
HC 
Kapiga, 
2009 [47] 
958, HIV negative 
women ages 16 
to 62 in Lusaka, 
Zambia (ZA), 
Moshi Tanzania 
(TZ) and 
Durban/Hlabisa, 
South Africa (SA), 
Incidence rate: 
31.9/100 PY (all 
sites) 
 
12M; every 
3M 
 
 
Vaginal swab via 
Gram stain using 
Nugent criteria 
 
Age, site, partner earns 
income, # sex partners, 
frequency vaginal sex in past 
1W, anal sex in past 3M, 
other STIs, bacterial 
vaginosis, candida, 
abnormal vaginal discharge 
on exam, abnormal cervical 
discharge on exam, incident 
HIV infection 
 
Final model (empirical 
selection): site and incident 
HIV infection included in SA 
model and only age in TZ/ZA 
model 
Not specified OCP All sites 
aOR: 0.6 (0.3, 
1.0) 
All sites DMPA 
aOR: 0.7 (0.5, 
1.0) 
 
All sites 
Norplant 
aOR: NR (ns) 
 
Pettifor, 
2009 [48] 
567, HIV-negative 
women ages 18 
to 40 recruited 
from family 
planning clinics in 
Orange Farm, 
South Africa; 
N=47 incident 
infectionsb, 
incident rate: 10.2 
per 100 PY 
1Y; 0M, 2M, 
6M, 8M and 
12M (NET-
EN users) or 
0M, 3M, 6M, 
9M and 
12M (DMPA 
users and 
controls) 
 
  
Vaginal swabs via 
culture in 
Diamond’s media  
Age, relationship status, 
education, frequency of sex 
past 3M, # partners in past 
3M, condom use in past 3M, 
vagina douching past 3M, 
age of first sex  
 
Final model (empirical and 
theoretical selection): Age, 
education, condom 
consistency in past 3M 
Non-pregnant 
non-hormonal 
user 
NA DMPA aIRR: 
0.35 (0.12, 
1.01); NET-EN 
aIRR: 0.63 
(0.30, 1.29) 
NA 
Pintye, 2017 
[49] 
1271, HIV-
negative women 
enrolled during 
pregnancy and 
followed until 9M 
postpartum in 
western Kenya, 
median age 22 
(IQR: 19-27), 
~14M; 20, 
24, 32 and 
36 weeks 
gestation 
and post 
partum (2, 6, 
10 and 14 
weeks; 6 and 
9 months) 
Self-collected 
vaginal swabs 
treated with 
metronidazole, 
detection via wet 
mount 
microscopy 
Final model (empirical 
selection): employment, 
male partner circumcision 
status, pregnancy status and 
other non-TV curable STIs 
(CT, NG, T. pallidum, BV or 
candidas) detected at 
enrolment. 
Non-hormonal 
user  
OCP aHR: NR 
(ns) 
 
Injectable 
(type not 
specified) 
aHR: NR (ns) 
 
Implant (type 
not specified) 
aHR: NR (ns) 
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Study N, study sample Length of 
follow-up; 
frequency 
STI 
assessment 
STI diagnostic 
test 
Covariates Reference 
group 
OCPa Injectable Implant or 
combined 
HC 
N=112 incident 
infectionsb; 10.4 
per 100 PY 
Romer, 
2013 [50] 
342, adolescent 
girls ages 14-17 
attending clinics 
in inner-city areas 
of Indianapolis, 
USA; N=80 
incident casesb 
Originally 
27M, 
extended to 
5Y for some 
participants; 
every 3M 
 
Detection of T 
vaginalis DNA 
was performed 
using a 
modification of 
the Amplicor 
CT/NG PCR assay 
that included 
primers and 
probes specific  
for T vaginalis. 
 
Age, positive STI test at start 
of period, # of partners in 
past 3M, # of lifetime 
partners, # of sexual events 
in last 3M (diary period), # 
of unprotected sexual 
events in last 3M (diary 
period) 
Non-hormonal 
user 
NA DMPA use in 
current 3M 
period aOR: 
OR: 0.66 
(0.32, 1.36); 
DMPA use in 
prior 3M aOR: 
1.04 (0.52, 
2.08) 
NA 
Notes: PY: person-years at risk. * Statistically significant at p<0.05.  
a OCP type was unspecified unless COC (combined oral contraception) ) or POP (progestin-only pill) is noted.  
b Multiple incident cases per woman were allowed, i.e., incident cases defined as a positive test following a negative test. 
c All women tested negative for T. vaginalis at baseline. Incident cases were number of T. vaginalis positive women at follow-up (only 1 follow-up). 
d Women censored after first T. vaginalis incident, or if became pregnant, acquired HIV or tested positive for CT or NG. N=211 women who tested positive for T. vaginalis at 
baseline were included and prescribed treatment; N=39 [18%] of these women were also infected at the subsequent visit.  
e Women censored after first T. vaginalis incident. 
f Injectable type not reported but authors note most commonly DMPA in setting with occasional norethisterone enanthate use. 
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Figure 1. PRISMA Flow Chart 
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Figure 2. Use of hormonal contraception and human papillomavirus (HPV) infection. 
 
Notes: Findings are presented from studies considered to be high and moderate quality. 
NR (ns): estimate not reported due to non-significance.  Estimated risk is log transformed adjusted odds ratio, adjusted hazard 
ratio or adjusted rate ratio; OCP: oral contraceptive pill; COC: combined oral contraceptive pill; DMPA: Depot 
Medroxyprogesterone Acetate. Studies which report multiple outcomes are distinguished by subgroup. 
 
 
 
  
Hormonal method
OCP
Injectable
Citation
Moscicki ,2001
Harris, 2009
Harris, 2009
Sellors 2003
Harris, 2009
Harris, 2009
Gosvig, 2013
Nielsen, 2009
Borgdorff, 2015
Marks, 2011
Marks, 2011
Shew, 2015
Nielsen, 2009
Winer, 2003
Nielsen, 2009
Nielsen, 2009
Shew, 2015
Shew, 2015
Phelan, 2009
Harris, 2009
Borgdorff, 2015
Shew, 2015
Marks, 2011
Marks, 2011
Shew, 2015
Harris, 2009
Shew, 2015
Harris, 2009
Harris, 2009
Contraceptive Use
Any OCP
COC, used  <2Yr
COC, used past 6M
Any OCP
COC,  used >2Yr
COC, last use >1Yr ago
Any OCP
Any OCP,  used <2Yr
Any OCP
COC
COC
Any OCP
Any OCP, used 3−4Yr
Any OCP
Any OCP used 5−6Yr
Any OCP used  7+Yr
Any OCP
Any OCP
Any OCP
DMPA , used <1Yr
Any injectable
DMPA
DMPA
DMPA
DMPA
DMPA, last use >1 Yr ago
DMPA
DMPA, used past 6M
DMPA , used >1Yr
Estimated Risk (95% CI)
−0.71 (−1.27, −0.15)
−0.69 (−1.61, 0.18)
−0.51 (−1.20, 0.41)
−0.36 (−1.61, 0.69)
−0.22 (−1.20, 0.69)
−0.11 (−1.20, 0.83)
0.00 (−1.56, 1.57)
0.01 (−0.39, 0.41)
0.08 (−1.56, 1.69)
0.20 (−0.21, 0.60)
0.24 (−0.07, 0.55)
0.27 (−0.31, 0.85)
0.33 (−0.02, 0.69)
0.34 (0.01, 0.59)
0.36 (0.00, 0.73)
0.51 (0.16, 0.85)
0.69 (0.25, 1.15)
1.00 (0.42, 1.59)
NR (ns)
−0.36 (−1.20, 0.74)
−0.24 (−1.08, 0.60)
−0.22 (−0.62, 0.17)
−0.14 (−0.60, 0.30)
−0.11 (−0.46, 0.27)
−0.04 (−0.40, 0.32)
0.26 (−0.51, 1.13)
0.45 (−0.11, 1.01)
0.47 (−0.36, 1.31)
1.55 (0.34, 2.76)
HPV Type
Any HPV
Any oncogenic HPV
Any oncogenic HPV
HR−HPV
Any oncogenic HPV
Any oncogenic HPV
Any HPV
HR−HPV
Any HPV
HR−HPV
Any HPV
HR−HPV
HR−HPV
Any HPV
HR−HPV
HR−HPV
Any HPV
LR−HPV
Any HPV
Any oncogenic HPV
Any HPV
HR−HPV
HR−HPV
Any HPV
Any HPV
Any oncogenic HPV
LR−HPV
Any oncogenic HPV
Any oncogenic HPV
−2 −1.5 −1 −0.5 0 0.5 1 1.5 2 2.5 3
Estimated Risk (log scale)
 45 
Figure 3. Use of hormonal contraception and C. trachomatis infection.  
 
 
Notes: Findings are presented from studies considered to be high and moderate quality. 
Estimated risk is log transformed adjusted odds ratio, adjusted hazard ratio or adjusted rate ratio; OCP: oral contraceptive pill; 
COC: combined oral contraceptive pill; DMPA: Depot Medroxyprogesterone Acetate. Studies which report multiple outcomes 
are distinguished by subgroup. 
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Figure 4. Use of hormonal contraception and N. gonorrhoeae infection. 
 
Notes: Findings are presented from studies considered to be high and moderate quality. 
Estimated risk is log transformed adjusted odds ratio, adjusted hazard ratio or adjusted rate ratio; OCP: oral contraceptive pill; 
COC: combined oral contraceptive pill; DMPA: Depot Medroxyprogesterone Acetate. Studies which report multiple outcomes 
are distinguished by subgroup.
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Figure 5. Use of hormonal contraception and T. vaginalis infection. 
  
Notes: Findings are presented from studies considered to be high and moderate quality. 
NR (ns): estimate not reported due to non-significance. Estimated risk is log transformed adjusted odds ratio, adjusted hazard 
ratio or adjusted rate ratio; OCP: oral contraceptive pill; COC: combined oral contraceptive pill; DMPA: Depot 
Medroxyprogesterone Acetate. Studies which report multiple outcomes are distinguished by subgroup.
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Supplemental Digital Content Figure 1 
Pubmed search string: 
  
((((((hormonal AND contracepti*) OR (“hormonal methods”)) OR ((progestin* OR progestins[MeSH] OR 
Progesterone[MeSH]) AND contracept*) OR (oral contracept*) OR OC OR POP OR ((((depo OR depot) AND 
medroxyprogesterone) OR depo medroxyprogesterone OR depo OR depot OR dmpa OR “Sayana Press” OR “net 
en” OR “NET-EN” OR “norethisterone enanthate” OR norethisterone-enanthate OR Medroxyprogesterone 17-
Acetate[MeSH]) AND (contracept* OR inject*)) OR “Depo Provera” OR “Depo-Provera” OR (((levonorgestrel OR 
etonogestrel) AND implant) OR (uniplant OR jadelle OR implanon OR nexplanon OR norplant OR norplant2 OR sino-
implant)) OR (hormonal, transdermal[MeSH] OR (contracept* AND patch)) OR (contracept* AND pill) OR 
((levonorgestrel AND (intrauterine devices[MeSH] OR iud OR iucd OR ius OR “intrauterine system” OR “intra-
uterine system” OR “intrauterine device” OR “intra-uterine device”)) OR mirena) OR ((combin* AND inject* AND 
contracept*) OR ((“once a month” OR monthly) AND inject* AND contracept*) OR (cyclofem OR lunell OR 
mesigyna OR “cyclo provera” OR cycloprovera)) OR ((((contraceptive devices[MeSH] OR contraceptive 
agents[MeSH]) AND ring) OR nuvaring OR “nuva ring”)) OR ((((contraceptive devices[MeSH] OR contraceptive 
agents[MeSH]) AND patch) OR “ortho evra” OR ortho evra)) AND (“Sexually Transmitted Infection”[MeSH] OR “STI” 
OR (“sexually transmitted infect*”) OR “STD” OR “Gonorrhea”[MeSH] OR “ gonorrhoeae” OR “Chlamydia”[MeSH] 
OR “chlamydia trachomatis” OR “Chancre”[MeSH] OR chancroid OR “haemophilus ducreyi” OR 
“Trichomonas”[MeSH] OR “Trichomoniasis”[MeSH] OR “trichomonas vaginalis” OR “TV” OR “Treponema 
pallidum”[MeSH] OR herpes OR herpesvirus OR “herpes simplex” OR “herpes virus” OR HSV OR “Human 
papillomavirus”[MeSH] OR “HPV” OR “Syphilis”[MeSH] OR “genital warts” OR “condylomata”)) OR (injectable 
contracepti* STI) OR (oral contracepti* STI) OR (CT OR GC OR NG AND “sexually transmitted infection”) OR (CT OR 
GC OR NG AND STI))) AND (“2009/01/01”[EDAT] : “2017/06/15”[EDAT])) 
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EMBASE search string  
  
hormonal AND contracepti* OR ‘hormonal methods’ OR (progestin* OR ‘progestins’ OR ‘progesterone’ AND 
contracept*) OR (‘oral’ AND contracept*) OR ‘OC’ OR ‘POP’ OR ((depo OR depot) AND ‘medroxyprogesterone’) OR 
depomedroxyprogesterone OR depo OR depot OR dmpa OR ‘sayana press’ OR ‘net en’ OR ‘net-en’ OR 
‘norethisterone enanthate’ OR ((‘medroxyprogesterone’ AND ’17-acetate’) AND (contracept* OR inject*)) OR 
((‘levonorgestrel’ OR ‘etonogestrel’) AND ‘implant’) OR ‘uniplant’ OR ‘jadelle’ OR ‘implanon’ OR ‘nexplanon’ OR 
‘norplant’ OR norplant2 OR ‘sino implant’ OR (hormonal AND transdermal) OR (contracept* AND patch) OR 
(‘levonorgestrel’ AND ‘intrauterine’ AND ‘devices’) OR ‘iud’ OR ‘iucd’ OR ius OR ‘intrauterine system’ OR ‘intra-
uterine system’ OR ‘intrauterine device’ OR ‘intra-uterine device’ OR ‘mirena’ OR (combin* AND inject* AND 
contracept*) OR ((‘once a month’ OR monthly) AND inject* AND contracept*) OR ‘cyclofem’ OR ‘lunelle’ OR 
‘mesigyna’ OR ‘cyclo provera’ OR ‘cycloprovera’ OR ((‘contraceptive’ AND ‘devices’) OR (‘contraceptive’ AND 
agents) AND ring) OR ‘nuvaring’ OR ‘nuva ring’ OR ((‘contraceptive’ AND ‘devices’) OR (‘contraceptive’ AND agents) 
AND patch) OR ‘ortho evra’ OR orthoevra AND (‘sexually transmitted infection’ OR STI OR ‘sexually transmitted 
infections’ OR STD ‘sexually transmitted disease’ OR ‘sexually transmitted diseases’ OR gonorrhea OR ‘neisseria 
gonorrhoeae’ OR chlamydia OR ‘chlamydia trachomatis’ OR chancre OR chancroid OR ‘haemophilus ducreyi’ OR 
trichomonas OR trichomoniasis OR ‘trichomonas vaginalis’ OR TV OR ‘treponema pallidum’ OR herpes OR 
herpesvirus OR ‘herpes simplex’ OR ‘herpes virus’ OR hsv OR ‘human papillomavirus’ OR hpv OR syphilis OR 
‘genital warts’ OR condylomata) OR (injectable contracepti* STI) OR (oral contracepti* STI) OR (CT OR GC OR NG 
AND ‘sexually transmitted infection’) OR (CT OR GC OR NG AND STI) AND [humans]/lim AND [1-1-2009]/sd NOT 
[15-6-2017]/sd AND ([article]/lim OR [article in press]/lim)
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Supplemental Digital Content Table 2: Quality assessment of prospective or retrospective cohort studies. 
Citation Study design Reference 
group drawn 
from same 
community as 
HC users (2) 
Ascertainment 
of HC use (2) 
Demonstration 
STI not present 
prior to 
incident/recurrent 
infection (1) 
Comparability 
of HC users 
and reference 
group cohorts 
demonstrated 
or adjusted 
for (2) 
Ascertainment 
of STI based 
on biomarker 
and blind to 
HC status (2) 
Adequate 
follow-up of 
cohort (<20% 
lost or 
unlikely to 
introduce 
bias) (1) 
Total score 
 
Quality rating: 
High (8-10) 
Medium (5-7) 
Low (<5) 
Balkus 2014 [34] Secondary 
RCT 
2 2 1 2 1 1 9 (High) 
Baeten 2001 [21] PC 2 2 0 2 1 0 7 (Medium) 
Barbone 1990 [24] Secondary 
RCT 
2 1 1 1 1 0 6 (Medium) 
Borgdorff 2015 [37] PC 2 2 1 2 1 1 9 (High) 
Brahmbhatt 2014 
[46] 
PC 1 1 1 2 1 0 6 (Medium) 
Chohan 2009 [53] PC 1 1 1 2 1 1 7 (Medium) 
Gosvig 2013 [38] PC 2 2 1 2 2 0 9 (High) 
Grabowski 2015 [35] Secondary 
RCT 
2 1 1 2 1 0 7 (Medium) 
Kapiga 2009 [47] PC 0 1 1 1 1 0 4 (Low) 
Lavreys 2004 [22] PC 1 2 0 1 1 0 5 (Medium) 
Lekovich 2015 [39] RC 2 1 1 1 1 0 6 (Medium) 
Louv 1989 [23] Secondary 
RCT 
1 2 1 1 1 0  6 (Medium) 
Louvanto 2011 [40] PC 0 1 1 1 1 0 4 (Low) 
Low 2014 [55] PC 1 2 1 1 0 0 5 (Medium) 
Marks 2011 [41] PC 2 2 1 2 1 0 8 (High) 
Masese 2013 [51] PC 1 2 1 2 1 0 7 (Medium) 
Morrison 2004 [25] PC 2 1 1 2 0 1 7 (Medium) 
Moscicki 2001 [26] PC 1 2 1 1 1 0 6 (Medium) 
Nielsen 2009 [42] PC 1 1 1 2 2 0 7 (Medium) 
Pettifor 2009 [48] PC 2 2 1 2 1 1 9 (High) 
Phelan 2009 [43] PC 1 2 1 1 1 0 6 (Medium) 
Pintye 2017 [49] PC 2 2 1 2 1 0 8 (High) 
Romer 2013 [50] PC 1 2 1 2 1 1 8 (High) 
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Russell 2016 [52] PC 1 2 1 2 1 1 8 (High) 
Sellors 2003 [28] PC 1 1 1 1 1 0 5 (Medium) 
Shew 2015 [44] PC 1 2 1 2 1 0 7 (Medium) 
Socias 2017 [54] PC 0 2 1 2 1 0 6 (Medium) 
Winer 2003 [27] PC 0 2 1 2 1 0 6 (Medium) 
Winer 2016 [45] PC 0 0 0 2 1 0 3 (Low) 
Notation: PC: prospective cohort, RC: retrospective cohort, Secondary RCT: secondary analysis of RCT. NR: not reported. NA: This criterion was not applicable: 
studies estimated recurrent infection. 
Rating criteria: Non-users drawn from same community as HC users: a) respondents drawn from the same community as HC users (i.e., does not include 
pregnant women) (1 point) and b) comparison group does not include users of another HC method (unless intentional head-to-head comparison (1 point). 
Ascertainment of HC use: a) separate estimates for different types of HCs (1 point), b) HC use assessed more than once and at intervals <6 months (1 point). 
Demonstration STI not present at start of study: test for pathogen used to confirm respondents were STI negative at study start (1 point). Comparability of 
cohorts demonstrated:  a) adjusted analyses performed (1 point); b) authors adjust for condom use or demonstrates negligible difference (1 point); 
Ascertainment of STI: a) independent blind assessment of STI performed (1 point); b) separate estimates for different types of STIs provided using test for 
pathogen (1 point); Adequacy of follow-up of cohorts: a) subjects lost to follow-up unlikely to introduce bias (either high retention >80% or description of those 
lost is provided and comparable to those who remain in the study) (1 point).   
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Supplemental Digital Content Table 3: Quality assessment of case-control studies. 
Citation STI case 
definition 
accurate (1) 
Representativeness 
of cases (1) 
Control 
selection (1) 
and 
definition (1)  
Comparability 
of cases and 
controls in 
design or 
analysis (2) 
Ascertainment 
of HC (3) 
Same 
ascertainment 
method for 
cases and 
controls (1) 
Comparable 
non-
response 
rate for cases 
and controls 
(1) 
Total score 
 
Quality 
rating: 
High (8-10) 
Medium (5-7) 
Low (<5) 
Harris 2009 [36] 1 0 2 1 2 1 0 7 (Medium) 
Rating criteria: STI definition accurate: separate estimates for different types of STIs provided using test for pathogen (1 point); Representation of cases: 
consecutive or obviously representative series of cases; Control selection & definition: a) controls are sampled independent of HC use and from same source 
population of cases (1 point); b) if cases are first occurrence of outcome, then controls stated to have no history of outcome. If cases have new (not necessarily 
first) occurrence of outcome, then controls with previous occurrences of outcome of interest are not excluded (1 point); Comparability of cases and controls in 
design or analysis: a) adjusted analyses are performed (1 point); b) study controls for condom use or negligible differences reported in adjusted in unadjusted 
models (1 point);  Ascertainment of HC:  a) separated estimates for different types of HCs (1 point); b) HC use is assessed more than once at intervals <6 
months (1 point); c) HC ascertainment is through structured interview blind to case-control status (1 point); Same ascertainment method for cases and 
controls: yes or no (1 point); Comparable non-response rate: equivalent rate demonstrated for both groups (1 point). 
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